

WEST Search History

DATE: Thursday, April 10, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L18	cyclosporin\$ same breast	32	L18
L17	herceptin same breast	25	L17
L16	herceptin same retino\$	2	L16
L15	herceptin adj10 retino\$	0	L15
L14	L13 and retino\$	16	L14
L13	(combination adj1 \$therapy) same cyclosporin\$	162	L13
L12	L10 and cyclosporin	381	L12
L11	L10 and herceptin	13	L11
L10	combination adj1 \$therapy	4099	L10
L9	l8 and retino\$	18	L9
L8	L7 and ((424/450)!.CCLS.)	46	L8
L7	L5 and target\$	236	L7
L6	L5 and antibod\$	215	L6
L5	L2 and peg	250	L5
L4	L3 and retino\$	24	L4
L3	L2 and (soybean adj1 oil)	35	L3
L2	liposome\$ same dimyristoyl\$	597	L2
L1	liposome\$ same (tertiary adj1 butyl)	22	L1

END OF SEARCH HISTORY

WEST Search History

DATE: Thursday, April 10, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
L18	cyclosporin\$ same breast	32	L18
L17	herceptin same breast	25	L17
L16	herceptin same retino\$	2	L16
L15	herceptin adj10 retino\$	0	L15
L14	L13 and retino\$	16	L14
L13	(combination adj1 \$therapy) same cyclosporin\$	162	L13
L12	L10 and cyclosporin	381	L12
L11	L10 and herceptin	13	L11
L10	combination adj1 \$therapy	4099	L10
L9	l8 and retino\$	18	L9
L8	L7 and ((424/450)!.CCLS.)	46	L8
L7	L5 and target\$	236	L7
L6	L5 and antibod\$	215	L6
L5	L2 and peg	250	L5
L4	L3 and retino\$	24	L4
L3	L2 and (soybean adj1 oil)	35	L3
L2	liposome\$ same dimyristoyl\$	597	L2
L1	liposome\$ same (tertiary adj1 butyl)	22	L1

END OF SEARCH HISTORY

WEST

☐ Generate Collection

Print

L1: Entry 13 of 22

File: USPT

May 19, 1998

DOCUMENT-IDENTIFIER: US 5753262 A

**** See image for Certificate of Correction ****

TITLE: Cationic lipid acid salt of 3beta[N- (N', N'-dimethylaminoethane) - carbamoyl]cholesterol and halogenated solvent-free preliposomal lyophilate thereof

Drawing Description Text (44):

Formulations of TCBs with the foregoing ratios of DC-Chol A or B and DOPE 20 were dissolved in a solvent mixture ranging from 100% tertiary-butyl alcohol to 30% tBA:70% water. Note that tBA is a non-halogenated solvent whose freezing point and vapor pressure are well suited for use in the practice of lyophilization. The formulated solutions of lipid and solvent were clear and essentially particle free. Such formulations in which the components form a clear solution lead to several advantages. Specifically, the solution can be sterile filtered and subsequently aseptically filled to give a sterile lyophilized vial of pre-liposomal TCB. This is a distinct advantage over the method disclosed by U.S. Pat. No. 5,283,185 (Epand et al.) -which requires size reduction of the DC-Chol liposomes by mechanical stress prior to filtration. Additionally, in preparations of the instant invention in which the lipids are not in the form of liposomes prior to lyophilization, and which result in a non-liposomal lyophilate, allow the preparation of the lyophilized TCB without cryoprotectants, since no liposomal particles are present to cryoprotect during lyophilization.



☐ Generate Collection Print

L1: Entry 11 of 22

File: USPT

Oct 13, 1998

DOCUMENT-IDENTIFIER: US 5820873 A

**** See image for Certificate of Correction ****

TITLE: Polyethylene glycol modified ceramide lipids and liposome uses thereof

Detailed Description Text (39):

A variety of methods are available for preparing liposomes as described in, e.g., Szoka et al., 9 ANN. REV. BIOPHYS. BIOENG. 467 (1980); U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028; the text LIPOSOMES Ch. 1 (supra) and Hope et al., 40 CHEM. PHYS. LIP. 89 (1986). One method produces multilamellar vesicles of heterogeneous sizes. In this method, the vesicle-forming lipids are dissolved in a suitable organic solvent or solvent system and dried under vacuum or an inert gas to form a thin lipid film. Alternatively, the lipids may be dissolved in an organic solvent such as tert-butyl alcohol or benzene:methanol (95:5 v/v) and lyophilized to form a homogeneous lipid mixture, which is in a more easily hydrated powder-like form. The dry lipid mixture is covered with an aqueous buffered solution and allowed to hydrate, typically over a 15-60 minute period with agitation. The size distribution of the resulting multilamellar vesicles can be shifted toward smaller sizes by hydrating the lipids under more vigorous agitation conditions. Full hydration of the lipids may be enhanced by freezing in liquid nitrogen and thawing to about 50.degree. C. This cycle is usually repeated about five times.

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 22 of 22 returned.**☐ 1. Document ID: US 6458381 B1

L1: Entry 1 of 22

File: USPT

Oct 1, 2002

US-PAT-NO: 6458381

DOCUMENT-IDENTIFIER: US 6458381 B1

TITLE: Lipids and their use, for example, in liposomes

DATE-ISSUED: October 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sourovov; Andrej	103009 Moscow			RU
Jung; Guenther	Tubingen			DE

US-CL-CURRENT: [424/450](#); [564/291](#)

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[RMC](#)☐ 2. Document ID: US 6447800 B2

L1: Entry 2 of 22

File: USPT

Sep 10, 2002

US-PAT-NO: 6447800

DOCUMENT-IDENTIFIER: US 6447800 B2

TITLE: Method of loading preformed liposomes using ethanol

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hope; Michael J.	Vancouver			CA

US-CL-CURRENT: [424/450](#); [264/4.1](#), [264/4.3](#), [264/4.6](#), [424/1.21](#), [424/417](#), [424/9.321](#), [424/9.51](#)

Full	Title	Classification	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[RMC](#)☐ 3. Document ID: US 6406667 B1

L1: Entry 3 of 22

File: USPT

Jun 18, 2002

US-PAT-NO: 6406667
DOCUMENT-IDENTIFIER: US 6406667 B1

TITLE: Chemiluminescent compositions for use in detection of multiple analytes

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Singh; Sharat	San Jose	CA		
Ullman; Edwin F.	Atherton	CA		

US-CL-CURRENT: 422/52; 422/61, 436/172, 436/534

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 4. Document ID: US 6372720 B1

L1: Entry 4 of 22

File: USPT

Apr 16, 2002

US-PAT-NO: 6372720
DOCUMENT-IDENTIFIER: US 6372720 B1

TITLE: Liposome fusion and delivery vehicle

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Longmuir; Kenneth J.	Irvine	CA	92612	
Waring; Alan J.	Irvine	CA	92614	
Haynes; Sherry M.	Irvine	CA	92612	

US-CL-CURRENT: 514/44; 424/450, 435/320.1, 435/455, 435/458, 514/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 5. Document ID: US 6348453 B1

L1: Entry 5 of 22

File: USPT

Feb 19, 2002

US-PAT-NO: 6348453
DOCUMENT-IDENTIFIER: US 6348453 B1

TITLE: Methods for treating viral infections

DATE-ISSUED: February 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ben-Hur; Ehud	New York	NY		

US-CL-CURRENT: [514/185](#); [424/450](#), [540/122](#), [540/131](#), [540/140](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMG
Draw Desc	Image									

☐ 6. Document ID: US 6326353 B1

L1: Entry 6 of 22

File: USPT

Dec 4, 2001

US-PAT-NO: 6326353

DOCUMENT-IDENTIFIER: US 6326353 B1

**** See image for Certificate of Correction ****

TITLE: Enhanced circulation effector composition and method

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zalipsky; Samuel	Fremont	CA		
Woodle; Martin C.	Menlo Park	CA		
Martin; Francis J.	San Francisco	CA		
Barenholz; Yechezkel	Jerusalem			IL

US-CL-CURRENT: [514/11](#); [424/450](#), [530/319](#), [530/812](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMG
Draw Desc	Image									

☐ 7. Document ID: US 6180134 B1

L1: Entry 7 of 22

File: USPT

Jan 30, 2001

US-PAT-NO: 6180134

DOCUMENT-IDENTIFIER: US 6180134 B1

**** See image for Certificate of Correction ****

TITLE: Enhanced ciruclation effector composition and method

DATE-ISSUED: January 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zalipsky; Samuel	Redwood City	CA		
Woodle; Martin C.	Menlo Park	CA		
Martin; Francis J.	San Francisco	CA		
Barenholz; Yechezkel	Jersusalem			IL

US-CL-CURRENT: [424/450](#); [530/319](#), [530/350](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMG
Draw Desc	Image									

☐ 8. Document ID: US 6103706 A

L1: Entry 8 of 22

File: USPT

Aug 15, 2000

US-PAT-NO: 6103706

DOCUMENT-IDENTIFIER: US 6103706 A

TITLE: Methods for treating viral infections

DATE-ISSUED: August 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ben-Hur; Ehud	New York	NY		

US-CL-CURRENT: 514/63; 514/183, 514/185, 514/191

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 9. Document ID: US 6010890 A

L1: Entry 9 of 22

File: USPT

Jan 4, 2000

US-PAT-NO: 6010890

DOCUMENT-IDENTIFIER: US 6010890 A

TITLE: Method for viral inactivation and compositions for use in same

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ben-Hur; Ehud	New York	NY		
Zuk; Maria M.	New York	NY		

US-CL-CURRENT: 435/173.3; 435/173.1, 435/2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 10. Document ID: US 5897873 A

L1: Entry 10 of 22

File: USPT

Apr 27, 1999

US-PAT-NO: 5897873

DOCUMENT-IDENTIFIER: US 5897873 A

TITLE: Affinity associated vaccine

DATE-ISSUED: April 27, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Popescu; Mircea	Plainsboro	NJ		

US-CL-CURRENT: 424/450; 424/204.1, 424/206.1, 424/208.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 11. Document ID: US 5820873 A

L1: Entry 11 of 22

File: USPT

Oct 13, 1998

US-PAT-NO: 5820873

DOCUMENT-IDENTIFIER: US 5820873 A

**** See image for Certificate of Correction ****

TITLE: Polyethylene glycol modified ceramide lipids and liposome uses thereof

DATE-ISSUED: October 13, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Choi; Lewis S. L.	Burnaby			CA
Madden; Thomas D.	Vancouver			CA
Webb; Murray S.	Vancouver			CA

US-CL-CURRENT: 424/283.1; 424/1.21, 424/184.1, 424/450, 424/812, 436/529, 436/535,
514/885

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 12. Document ID: US 5776488 A

L1: Entry 12 of 22

File: USPT

Jul 7, 1998

US-PAT-NO: 5776488

DOCUMENT-IDENTIFIER: US 5776488 A

TITLE: Liposome preparation

DATE-ISSUED: July 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mori; Yoshiyuki	Chikujo-gun			JP
Sagara; Kazuyoshi	Chikujo-gun			JP
Mizuta; Hiroaki	Chikujo-gun			JP
Fujii; Akihiro	Iruma			JP

US-CL-CURRENT: 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 13. Document ID: US 5753262 A

L1: Entry 13 of 22

File: USPT

May 19, 1998

US-PAT-NO: 5753262

DOCUMENT-IDENTIFIER: US 5753262 A

**** See image for Certificate of Correction ****

TITLE: Cationic lipid acid salt of 3beta[N- (N', N'-dimethylaminoethane) - carbamoyl]cholesterol and halogenated solvent-free preliposomal lyophilate thereof

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wyse; Joseph W.	The Woodlands	TX		
Warner; Charles D.	The Woodlands	TX		

US-CL-CURRENT: 424/450; 435/458, 436/71, 552/545

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 14. Document ID: US 5723146 A

L1: Entry 14 of 22

File: USPT

Mar 3, 1998

US-PAT-NO: 5723146

DOCUMENT-IDENTIFIER: US 5723146 A

TITLE: Pharmaceutical preparations

DATE-ISSUED: March 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rossling; Georg	Berlin			DE
Sachse; Andreas	Berlin			DE
Riedl; Jutta	Berlin			DE

US-CL-CURRENT: 424/450; 514/859, 514/880

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 15. Document ID: US 5620689 A

L1: Entry 15 of 22

File: USPT

Apr 15, 1997

US-PAT-NO: 5620689

DOCUMENT-IDENTIFIER: US 5620689 A

TITLE: Liposomes for treatment of B-cell and T-cell disorders

DATE-ISSUED: April 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Allen; Theresa M.	Edmonton			CA
Martin; Francis J.	San Francisco	CA		

US-CL-CURRENT: 424/178.1; 424/180.1, 424/181.1, 424/450, 424/812, 530/391.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 16. Document ID: US 5498420 A

L1: Entry 16 of 22

File: USPT

Mar 12, 1996

US-PAT-NO: 5498420

DOCUMENT-IDENTIFIER: US 5498420 A

**** See image for Certificate of Correction ****

TITLE: Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions

DATE-ISSUED: March 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mentrup Edgar	Frankfurt			DE
Michel; Christoph	Obertshausen			DE
Purmann; Thomas	Aschaffenburg			DE

US-CL-CURRENT: 424/450; 424/401

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 17. Document ID: US 4978625 A

L1: Entry 17 of 22

File: USPT

Dec 18, 1990

US-PAT-NO: 4978625

DOCUMENT-IDENTIFIER: US 4978625 A

TITLE: Fluorescence immunoassay using water insoluble dyes

DATE-ISSUED: December 18, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Daniel B.	Raleigh	NC		
Vonk; Glenn P.	Fuquay-Varina	NC		
Mercolino; Thomas J.	Chapel Hill	NC		

US-CL-CURRENT: 436/518; 436/528, 436/546, 436/800, 436/808, 436/829

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 18. Document ID: US 4826961 A

L1: Entry 18 of 22

File: USPT

May 2, 1989

US-PAT-NO: 4826961

DOCUMENT-IDENTIFIER: US 4826961 A

TITLE: Method for preparing radiopharmaceutical complexes

DATE-ISSUED: May 2, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jones; Alun G.	Newton Centre	MA		
Davison; Alan	Needham	MA		
Abrams; Michael J.	Westchester	PA		

US-CL-CURRENT: 534/14; 252/644, 252/645, 987/19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 19. Document ID: US 4707544 A

L1: Entry 19 of 22

File: USPT

Nov 17, 1987

US-PAT-NO: 4707544

DOCUMENT-IDENTIFIER: US 4707544 A

TITLE: Metal-isonitrile adducts for preparing radionuclide complexes for labelling and imaging agents

DATE-ISSUED: November 17, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jones; Alun G.	Newton Centre	MA		
Davison; Alan	Needham	MA		
Abrams; Michael J.	Westchester	PA		

US-CL-CURRENT: 424/1.17; 424/1.21, 534/10, 534/14, 556/1, 556/118, 556/37, 556/64, 556/81, 558/302, 987/19

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 20. Document ID: US 4452774 A

L1: Entry 20 of 22

File: USPT

Jun 5, 1984

US-PAT-NO: 4452774

DOCUMENT-IDENTIFIER: US 4452774 A

**** See image for Certificate of Correction ****

TITLE: Isonitrile radionuclide complexes for labelling and imaging agents

DATE-ISSUED: June 5, 1984

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jones; Alun G.	Newton Centre	MA		
Davison; Alan	Needham	MA		
Abrams; Michael J.	Allston	MA		

US-CL-CURRENT: 424/1.65; 424/1.17, 424/1.21, 534/10, 534/14, 558/302, 987/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 21. Document ID: JP 58035109 A

L1: Entry 21 of 22

File: JPAB

Mar 1, 1983

PUB-NO: JP358035109A

DOCUMENT-IDENTIFIER: JP 58035109 A

TITLE: PHOSPHOLIPID LIPOSOME CLATHRATE WITH IRON (2) PORPHYRIN COMPLEX HAVING PROXIMATE BASES AND OXYGEN ADSORPTION AND DESORPTION AGENT

PUBN-DATE: March 1, 1983

INVENTOR-INFORMATION:

NAME	COUNTRY
HASEGAWA, ETSUO	
TSUCHIDA, HIDETOSHI	

US-CL-CURRENT: 540/145

INT-CL (IPC): A61K 9/56; A61K 31/415; A61K 9/10; C07D 487/22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Clip Img	Image								

☐ 22. Document ID: JP 58035109 A JP 84025768 B

L1: Entry 22 of 22

File: DWPI

Mar 1, 1983

DERWENT-ACC-NO: 1983-33704K

DERWENT-WEEK: 198314

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Phospholipid liposome contg. iron (II) porphyrin complex - can reversibly absorb oxygen depending on the partial pressure

PRIORITY-DATA: 1981JP-0134983 (August 28, 1981)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 58035109 A	March 1, 1983		005	
JP 84025768 B	June 21, 1984		000	

INT-CL (IPC): A61K 9/56; A61K 31/41; C07D 487/22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	HOME
Draw Desc	Image									

[Generate Collection](#)[Print](#)

Terms	Documents
liposome\$ same (tertiary adj 1 butyl)	22

Display Format:

-

[Change Format](#)[Previous Page](#)[Next Page](#)



☐

L3: Entry 30 of 35

File: USPT

Oct 31, 1995

DOCUMENT-IDENTIFIER: US 5463066 A

**** See image for Certificate of Correction ****

TITLE: Phospholipid derivative and reactive vesicle-forming agent

Brief Summary Text (48):

Thus, the reactive vesicle-forming agent according to the present invention comprises the phospholipid derivative represented by the general formula (1) which can be used each solely or in combination of two or more of them or, further, in combination with other vesicle-forming component(s), for example, other phospholipids, such as soybean lecithin and yolk lecithin, cholesterol, Intralipid (Trademark, Otsuka Pharmaceutical Co., Ltd.), soybean oil and safflower oil, to form a reactive vesicle, such as a reactive liposome, reactive fatty emulsion or a reactive micell. These vesicles may be produced by known methods.

Brief Summary Text (64):

For a reactive vesicle other than liposome, a reactive fatty emulsion may be employed, which is prepared by emulsifying an oily mixture containing a phospholipid derivative represented by the general formula (1), a vegetable oil component, such as soybean oil and safflower oil, and an unmodified phospholipid component (another phospholipid component), such as soybean lecithin and yolk lecithin, in an aqueous emulsion medium together with other optionally employed additives, such as Intralipid (Trademark, Ohtsuka Pharmac. Co.), emulsifying assistants, stabilizers, isotonizing agents, oil-soluble medicaments and oil-soluble physiological substances. In these reactive fatty emulsions, the phospholipid derivative of the general formula (1) and other membrane-forming components are drawn up towards the interface between the oil phase of the oil droplets and the aqueous phase surrounding it and accumulate there to form a vesicle.

Detailed Description Text (61):

The procedures of Example 4-1 were pursued with the exception that 5% by weight (1 .mu.mol) of a reactive phospholipid derivative of the general formula (1-3) in which both R.sup.1 C(.dbd.O) and R.sup.2 C(.dbd.O) are a myristoyl group, R.sup.3 denotes a hydrogen atom, M denotes a sodium atom, OA is an oxyethylene group and n is a number of about 10 and 5% by weight (0.4 .mu.mol) of dimyristoyl-glycero-phospho polyethylene glycol (MW=ca. 2,000) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size=268 nm, CV value=22%).

Detailed Description Text (65):

The procedures of Example 4-1 were pursued with the exception that 1% by weight (0.1 .mu.mol) of a reactive phospholipid derivative of the general formula (1-3), in which both R.sup.1 C(.dbd.O) and R.sup.2 C(.dbd.O) are a stearyl group, R.sup.3 denotes a hydrogen atom, M denotes a sodium atom and the oxyalkylene chain consists of a random addition polymeric chain composed of oxypropylene groups (average addition mole number=ca. 10) and oxyethylene groups (average addition mole number=ca. 25), and 5% by weight (0.4 .mu.mol) of dimyristoyl-glycero-phospho polyethylene glycol (MW=ca. 2,000) were used in the place of the reactive phospholipid derivative of Example 2-1, whereby a reactive liposome was obtained (average particle size=239 nm, CV value=25%).

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 24 of 24 returned.**☐ 1. Document ID: US 6537246 B1

L4: Entry 1 of 24

File: USPT

Mar 25, 2003

US-PAT-NO: 6537246

DOCUMENT-IDENTIFIER: US 6537246 B1

TITLE: Oxygen delivery agents and uses for the same

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
McCreery; Thomas	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 604/82; 222/145.5, 222/145.6, 222/146.2, 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[None](#)☐ 2. Document ID: US 6527759 B1

L4: Entry 2 of 24

File: USPT

Mar 4, 2003

US-PAT-NO: 6527759

DOCUMENT-IDENTIFIER: US 6527759 B1

TITLE: Ultrasound assembly for use with light activated drugs

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tachibana; Katsuro	Fukuoka			JP
Tachibana; Shunro	Fukuoka			JP
Anderson; James R.	Redmond	WA		
Lichttenegger; Gary	Woodinville	WA		

US-CL-CURRENT: 604/500; 604/22, 604/509, 604/522

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[None](#)

☐ 3. Document ID: US 6479034 B1

L4: Entry 3 of 24

File: USPT

Nov 12, 2002

US-PAT-NO: 6479034

DOCUMENT-IDENTIFIER: US 6479034 B1

TITLE: Method of preparing gas and gaseous precursor-filled microspheres

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 424/9.51; 424/450, 424/459, 424/9.5, 424/9.52

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 4. Document ID: US 6444660 B1

L4: Entry 4 of 24

File: USPT

Sep 3, 2002

US-PAT-NO: 6444660

DOCUMENT-IDENTIFIER: US 6444660 B1

TITLE: Lipid soluble steroid prodrugs

DATE-ISSUED: September 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Shen; DeKang	Tucson	AZ		

US-CL-CURRENT: 514/180

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 5. Document ID: US 6443898 B1

L4: Entry 5 of 24

File: USPT

Sep 3, 2002

US-PAT-NO: 6443898

DOCUMENT-IDENTIFIER: US 6443898 B1

TITLE: Therapeutic delivery systems

DATE-ISSUED: September 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 600/458; 424/450, 424/9.51

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 6. Document ID: US 6416740 B1

L4: Entry 6 of 24

File: USPT

Jul 9, 2002

US-PAT-NO: 6416740

DOCUMENT-IDENTIFIER: US 6416740 B1

TITLE: Acoustically active drug delivery systems

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.5, 424/9.51

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 7. Document ID: US 6403056 B1

L4: Entry 7 of 24

File: USPT

Jun 11, 2002

US-PAT-NO: 6403056

DOCUMENT-IDENTIFIER: US 6403056 B1

**** See image for Certificate of Correction ****

TITLE: Method for delivering bioactive agents using cochleates

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: [424/9.51](#); [424/400](#), [424/450](#), [424/502](#), [424/9.52](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 8. Document ID: US 6200597 B1

L4: Entry 8 of 24

File: USPT

Mar 13, 2001

US-PAT-NO: 6200597

DOCUMENT-IDENTIFIER: US 6200597 B1

**** See image for Certificate of Correction ****

TITLE: Formulation and use of carotenoids in treatment of cancer

DATE-ISSUED: March 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mehta; Kapil	Houston	TX		
Perez-Soler; Roman	Houston	TX		
Lopez-Berestein; Gabriel	Houston	TX		
Lenk; Robert	Willis	TX		
Hayman; Alan C.	late of The Woodlands	TX		

US-CL-CURRENT: [424/450](#); [514/725](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 9. Document ID: US 6176842 B1

L4: Entry 9 of 24

File: USPT

Jan 23, 2001

US-PAT-NO: 6176842

DOCUMENT-IDENTIFIER: US 6176842 B1

TITLE: Ultrasound assembly for use with light activated drugs

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tachibana; Katsuro	Fukuoka			JP
Tachibana; Shunro	Fukuoka			JP
Anderson; James R.	Redmond	WA		
Lichttenegger; Gary	Woodinville	WA		

US-CL-CURRENT: [604/22](#); [604/101.03](#), [604/102.03](#), [604/103.01](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 10. Document ID: US 6143276 A

L4: Entry 10 of 24

File: USPT

Nov 7, 2000

US-PAT-NO: 6143276

DOCUMENT-IDENTIFIER: US 6143276 A

TITLE: Methods for delivering bioactive agents to regions of elevated temperatures

DATE-ISSUED: November 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 424/9.3; 424/450, 424/455, 424/489, 424/491, 424/497, 424/499,
424/502, 424/9.4, 424/9.52

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 11. Document ID: US 6123923 A

L4: Entry 11 of 24

File: USPT

Sep 26, 2000

US-PAT-NO: 6123923

DOCUMENT-IDENTIFIER: US 6123923 A

TITLE: Optoacoustic contrast agents and methods for their use

DATE-ISSUED: September 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Wu; Yunqiu	Tucson	AZ		

US-CL-CURRENT: 424/9.52; 424/450, 424/9.1, 424/9.2, 424/9.3, 424/9.6, 514/410

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 12. Document ID: US 6120751 A

L4: Entry 12 of 24

File: USPT

Sep 19, 2000

US-PAT-NO: 6120751

DOCUMENT-IDENTIFIER: US 6120751 A

TITLE: Charged lipids and uses for the same

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 424/9.51; 264/4, 264/4.1, 424/450, 424/502, 424/9.52, 428/402.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMHC
Draw Desc	Image									

☐ 13. Document ID: US 6090800 A

L4: Entry 13 of 24

File: USPT

Jul 18, 2000

US-PAT-NO: 6090800

DOCUMENT-IDENTIFIER: US 6090800 A

TITLE: Lipid soluble steroid prodrugs

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Shen; DeKang	Tucson	AZ		

US-CL-CURRENT: 514/180; 552/574

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMHC
Draw Desc	Image									

☐ 14. Document ID: US 6028066 A

L4: Entry 14 of 24

File: USPT

Feb 22, 2000

US-PAT-NO: 6028066

DOCUMENT-IDENTIFIER: US 6028066 A

TITLE: Prodrugs comprising fluorinated amphiphiles

DATE-ISSUED: February 22, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		

US-CL-CURRENT: 514/180; 514/169, 552/507

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMHC
Draw Desc	Image									

☐ 15. Document ID: US 5853752 A

L4: Entry 15 of 24

File: USPT

Dec 29, 1998

US-PAT-NO: 5853752

DOCUMENT-IDENTIFIER: US 5853752 A

**** See image for Certificate of Correction ****

TITLE: Methods of preparing gas and gaseous precursor-filled microspheres

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 264/4.6, 424/1.21, 424/489, 424/9.321,
424/9.51, 436/829

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 16. Document ID: US 5811119 A

L4: Entry 16 of 24

File: USPT

Sep 22, 1998

US-PAT-NO: 5811119

DOCUMENT-IDENTIFIER: US 5811119 A

**** See image for Certificate of Correction ****

TITLE: Formulation and use of carotenoids in treatment of cancer

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mehta; Kapil	Houston	TX		
Perez-Soler; Roman	Houston	TX		
Lopez-Berestein; Gabriel	Houston	TX		
Lenk; Robert P.	Willis	TX		
Hayman, deceased; Alan C.	late of Houston	TX		

US-CL-CURRENT: 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 17. Document ID: US 5770222 A

L4: Entry 17 of 24

File: USPT

Jun 23, 1998

US-PAT-NO: 5770222

DOCUMENT-IDENTIFIER: US 5770222 A

TITLE: Therapeutic drug delivery systems

DATE-ISSUED: June 23, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 264/4.6, 424/1.21, 424/489, 424/9.321,
424/9.51, 436/829

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

RMC

☐ 18. Document ID: US 5733572 A

L4: Entry 18 of 24

File: USPT

Mar 31, 1998

US-PAT-NO: 5733572

DOCUMENT-IDENTIFIER: US 5733572 A

**** See image for Certificate of Correction ****

TITLE: Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles

DATE-ISSUED: March 31, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Matsunaga; Terry O.	Tucson	AZ		
Yellowhair; David	Tucson	AZ		

US-CL-CURRENT: 424/450; 424/1.21, 424/489, 424/9.321, 424/9.4, 436/829

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

RMC

☐ 19. Document ID: US 5585112 A

L4: Entry 19 of 24

File: USPT

Dec 17, 1996

US-PAT-NO: 5585112

DOCUMENT-IDENTIFIER: US 5585112 A

**** See image for Certificate of Correction ****

TITLE: Method of preparing gas and gaseous precursor-filled microspheres

DATE-ISSUED: December 17, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 424/450; 264/4.1, 264/4.3, 424/9.51

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 20. Document ID: US 5580575 A

L4: Entry 20 of 24

File: USPT

Dec 3, 1996

US-PAT-NO: 5580575

DOCUMENT-IDENTIFIER: US 5580575 A

**** See image for Certificate of Correction ****

TITLE: Therapeutic drug delivery systems

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 424/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 21. Document ID: US 5542935 A

L4: Entry 21 of 24

File: USPT

Aug 6, 1996

US-PAT-NO: 5542935

DOCUMENT-IDENTIFIER: US 5542935 A

**** See image for Certificate of Correction ****

TITLE: Therapeutic delivery systems related applications

DATE-ISSUED: August 6, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Unger; Evan C.	Tucson	AZ		
Fritz; Thomas A.	Tucson	AZ		
Matsunaga; Terry	Tucson	AZ		
Ramaswami; VaradaRajan	Tucson	AZ		
Yellowhair; David	Tucson	AZ		
Wu; Guanli	Tucson	AZ		

US-CL-CURRENT: 604/190; 424/450, 600/458

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 22. Document ID: US 5139803 A

L4: Entry 22 of 24

File: USPT

Aug 18, 1992

US-PAT-NO: 5139803

DOCUMENT-IDENTIFIER: US 5139803 A

TITLE: Method and liposome composition for the stabilization of oxidizable substances

DATE-ISSUED: August 18, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Haynes; Lynn C.	Morris Plains	NJ		
Levine; Harry	Morris Plains	NJ		
Finley; John W.	Whippany	NJ		

US-CL-CURRENT: 426/330.6; 426/602

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 23. Document ID: US 5015483 A

L4: Entry 23 of 24

File: USPT

May 14, 1991

US-PAT-NO: 5015483

DOCUMENT-IDENTIFIER: US 5015483 A

TITLE: Liposome composition for the stabilization of oxidizable substances

DATE-ISSUED: May 14, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Haynes; Lynn C.	Morris Plains	NJ		
Levine; Harry	Morris Plains	NJ		
Finley; John W.	Whippany	NJ		

US-CL-CURRENT: 426/73; 426/311, 426/603

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

☐ 24. Document ID: US 20020143062 A1 WO 200232413 A2 AU 200211776 A

L4: Entry 24 of 24

File: DWPI

Oct 3, 2002

DERWENT-ACC-NO: 2002-519137

DERWENT-WEEK: 200267

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Preparation of a retinoid composition, useful for treating cancer, involves mixing at least one retinoid or its derivative with dimyristoyl phosphatidylcholine, soybean oil, tertiarybutyl alcohol and water

INVENTOR: LIM, S; LOPEZ-BERESTEIN, G ; TARI, A M

PRIORITY-DATA: 2000US-241445P (October 17, 2000), 2001US-0982113 (October 17, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020143062 A1	October 3, 2002		000	A61K039/395
WO 200232413 A2	April 25, 2002	E	112	A61K031/00
AU 200211776 A	April 29, 2002		000	A61K031/00

INT-CL (IPC): A61 K 9/127; A61 K 31/00; A61 K 31/16; A61 K 39/395

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

Generate Collection

Print

Terms	Documents
L3 and retino\$	24

Display Format: Change Format[Previous Page](#)[Next Page](#)

WEST



Generate Collection

Print

L8: Entry 30 of 46

File: USPT

Aug 18, 1998

DOCUMENT-IDENTIFIER: US 5795589 A

**** See image for Certificate of Correction ****

TITLE: Liposomal antineoplastic agent compositions

Brief Summary Text (10):

As has been established by various investigators, cancer therapy employing antineoplastic agents can in many cases be significantly improved by encapsulating the antineoplastic agent in liposomes using traditional methods, rather than administering the free agent directly into the body. See, for example, Forssen, et al., (1983), Cancer Res., 43:546; and Gabizon et al., (1982), Cancer Res., 42:4734. Passive incorporation of such agents in liposomes can change their antitumor activities, clearance rates, tissue distributions, and toxicities compared to direct administration. See, for example, Rahman et al., (1982), Cancer Res., 42:1817; Rosa, et al., (1982) in Transport in Biomembranes: Model Systems and Reconstitution, R. Antoline et al., ed. Raven Press, New York. 243-256; Rosa, et al., (1983), Pharmacology, 26:221; Gabizon et al., (1983), Cancer Res., 43:4730; Forssen et al., supra; Gabizon, et al., supra; and Olson, et al., (1982), Br. J. Cancer Clin. Oncol., 18:167. Utilizing liposomes of various composition and size, evidence has been gathered demonstrating that the acute and chronic toxicities of doxorubicin can be attenuated by directing the drug away from target organs. For example, it is known that the cardiotoxicity of the anthracycline antibiotics daunorubicin and doxorubicin and their pharmaceutically acceptable derivatives and salts can be significantly reduced through passive liposome encapsulation. See, for example, Forssen et al., supra; Olson et al., supra; and Rahman et al., supra. This buffering of toxicity appears mainly to arise from reduced accumulation into the heart, with associated reduction in cardiotoxicity (Rahman et al., 1980 Cancer Res., 40:1532; Olson et al., supra.; Herman et al., 1983, Cancer Res., 43:5427; and Rahman et al., 1985, Cancer Res., 45:796). Such toxicity is normally dose limiting for free doxorubicin (Minow et al., 1975, Cancer Chemother. Rep. 6:195). Incorporation of highly toxic antineoplastic agents in liposomes can also reduce the risk of exposure to such agents by persons involved in their administration.

Brief Summary Text (16):

Liposomes themselves have been reported to have no significant toxicities in previous human clinical trials where they have been given intravenously. Richardson et al., (1979), Br. J. Cancer 40:35; Ryman et al., (1983) in "Targeting of Drugs" G. Gregoriadis, et al., eds. pp 235-248, Plenum, N.Y.; Gregoriadis G., (1981), Lancet 2:241, and Lopez-Berestein et al., (1985) J. Infect. Dis., 151:704. Liposomes are reported to concentrate predominately in the reticuloendothelial organs lined by sinusoidal capillaries, i.e., liver, spleen, and bone marrow, and phagocytosed by the phagocytic cells present in these organs.

Brief Summary Text (22):

The present invention discloses a liposome composition that comprises an antineoplastic agent and a lipid preferably a phospholipid, such as EPC and cholesterol, and wherein the liposomes have a transmembrane ion gradient preferably a pH gradient. The liposomes have a drug (antineoplastic agent) to lipid ratio of about greater than about 0.1:1 to about 3:1, most preferably about 0.3:1 to 3:1. The liposomes contain a release-inhibiting buffer combination such as citric acid/sodium carbonate, citric acid/sodium bis phosphate, or sodium carbonate/potassium sulfate-HEPES. The antineoplastic agent can be for example, an anthracycline such as doxorubicin, daunorubicin, or epirubicin, a vinca alkaloid such as vinblastine, or

vincristine, a purine or pyrimidine derivative such as 5-fluorouracil, an alkylating agent such as mitoxanthrone, mechlorethamine hydrochloride or cyclophosphamide, or an antineoplastic antibiotic such as mitomycin or bleomycin. The liposomes may comprise phospholipid such as egg phosphatidylcholine ("EPC"), hydrogenated soy phosphatidylcholine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, or diarachidonoylphosphatidylcholine, and may additionally comprise cholesterol, for example, in about a 55:45 phospholipid:cholesterol mol ratio. The liposomes may additionally comprise alpha tocopherol. The liposomes can be about 30 nm to about 2 microns in size, preferably about 100 to about 300 nm in diameter; large unilamellar vesicles. They can contain about 50 to 200 mg/ml lipid, more preferably about 90 to about 110 mg/ml lipid. The entrapment of the antineoplastic agent in the liposomes is from about 50% to about 100%, preferably about 90% to about 100%, more preferably about 98 to about 100%. These liposome may be large unilamellar vesicles, and may be homogeneous or unimodal with regard to size distribution. The liposomes may be administered intravenously in a patient. Pharmaceutical preparations containing the antineoplastic agents entrapped in the liposomes and pharmaceutically acceptable carriers or diluents are another embodiment of the present invention. The liposome compositions of the invention may be used to treat or stabilize a neoplastic disease, or prophylactically to prevent the onset or recurrence of a neoplastic disease. The composition of the present invention is, for example, provided as a three-component system. Where the antineoplastic agent is doxorubicin, the three component system comprises empty liposomes in an acidic solution of about pH 4.0, a basic solution, and the antineoplastic agent. The acidic solution is acetic acid buffer, oxalic acid buffer, or succinic acid buffer, preferably aqueous citric acid buffer. The basic solution is preferably sodium carbonate. The drug to lipid weight ratio is greater than about 0.1:1 to about 3:1.

Detailed Description Text (9):

In addition to loading a single antineoplastic agent, the pH gradient loading method can be used to load multiple antineoplastic agents, either simultaneously or sequentially. Also, the liposomes into which the ionizable antineoplastic agents are loaded may themselves be pre-loaded with other antineoplastic agents or other drugs using conventional passive encapsulation techniques (e.g., by incorporating the drug in the buffer from which the liposomes are made). Since the conventionally loaded materials need not be ionizable, this approach provides great flexibility in preparing liposome-encapsulated "drug cocktails" for use in cancer therapies. These "drug cocktails" may also comprise two or more populations of liposomes (which entrap the same or different antineoplastic agents), comprise different lipid formulations, or comprise different vesicle sizes. Such cocktails may be administered in order to achieve greater therapeutic efficacy, safety, prolonged drug release or targeting.

Detailed Description Text (18):

Lipids which can be used in the liposome formulations of the present invention include phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidic acid (PA), phosphatidylinositol (PI), sphingomyelin (SPM), and the like, alone or in combination. The phospholipids can be synthetic or derived from natural sources such as egg or soy. The phospholipids dimyristoylphosphatidylcholine (DMPC) and dimyristoylphosphatidylglycerol (DMPG) may also be used. In the preferred embodiments, egg phosphatidylcholine (EPC), and cholesterol are used in preferably a 55:45 mole ratio. In other embodiments, distearoylphosphatidyl choline (DSPC), dipalmitoylphosphatidylcholine (DPPC), or hydrogenated soy phosphatidylcholine (HSPC) may be used in a mole ratio of 55:45 with cholesterol. Dimyristoylphosphatidylcholine (DMPC) and diarachidonoyl phosphatidylcholine (DAPC) may similarly be used. Due to the elevated transition temperatures ($T_{sub.c}$) of lipids such as DSPC ($T_{sub.c}$ of about 65.degree. C.), DPPC ($T_{sub.c}$ of about 45.degree. C.), and DAPC ($T_{sub.c}$ of about 85.degree. C.), such lipids are preferably heated to about their $T_{sub.c}$ or temperatures slightly higher (e.g., up to about 5.degree. C. higher) than the $T_{sub.c}$ in order to make these liposomes.

Detailed Description Text (19):

The liposomes can also contain other steroid components such as polyethylene glycol derivatives of cholesterol (PEG-cholesterols), coprostanol, cholestanol, or cholestane, or alpha-tocopherol. They may also contain organic acid derivatives of

sterols such as cholesterol hemisuccinate (CHS), and the like. Organic acid derivatives of tocopherols may also be used as liposome-forming ingredients, such as alpha-tocopherol hemisuccinate (THS). Both CHS- and THS-containing liposomes and their tris salt forms may generally be prepared by any method known in the art for preparing liposomes containing these sterols. In particular, see the procedures of Janoff, et al., U.S. Pat. No. 4,721,612, issued Jan. 26, 1988, entitled "Steroidal Liposomes", and Janoff, et al., PCT Publication No. 87/02219, published Apr. 23, 1987, entitled "Alpha Tocopherol-Based Vesicles", relevant portions of which are incorporated herein by reference. The liposomes may also contain glycolipids.

Current US Original Classification (1):
424/450

Other Reference Publication (6):
Gregoriadis, G. "Targeting Drugs", The Lancet (1981) 2:241.

Other Reference Publication (19):
Ryman et al. in "Targeting of Drugs" G. Gregoriadis et al. eds. pp. 235-248, Plenum, N.Y..

CLAIMS:

20. The dehydrated liposome of claim 15, wherein said lipid comprises at least one phospholipid selected from the group consisting of egg phosphatidylcholine (EPC); distearoyl phosphatidylcholine (DSPC); hydrogenated soy phosphatidylcholine (HSPC); dipalmitoyl phosphatidylcholine (DPPC); dimyristoyl phosphatidylcholine (DMPC); and diarachidonoyl phosphatidylcholine (DAPC).

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 13 of 13 returned.☐ 1. Document ID: US 6537988 B2

L11: Entry 1 of 13

File: USPT

Mar 25, 2003

US-PAT-NO: 6537988

DOCUMENT-IDENTIFIER: US 6537988 B2

TITLE: Synergistic methods and compositions for treating cancer

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Francis Y.	Yardley	PA		

US-CL-CURRENT: 514/221; 514/2, 514/449, 514/8, 514/922

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 2. Document ID: US 6537579 B1

L11: Entry 2 of 13

File: USPT

Mar 25, 2003

US-PAT-NO: 6537579

DOCUMENT-IDENTIFIER: US 6537579 B1

TITLE: Compositions and methods for administration of pharmacologically active compounds

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Desai; Neil P.	Los Angeles	CA		
Soon-Shiong; Patrick	Los Angeles	CA		

US-CL-CURRENT: 424/489

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 3. Document ID: US 6528640 B1

L11: Entry 3 of 13

File: USPT

Mar 4, 2003

US-PAT-NO: 6528640

DOCUMENT-IDENTIFIER: US 6528640 B1

TITLE: Synthetic ribonucleic acids with RNase activity

DATE-ISSUED: March 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Beigelman; Leonid	Broomfield	CO		
Burgin; Alex	Chula Vista	CA		
Beaudry; Amber	Broomfield	CO		
Karpeisky; Alexander	Lafayette	CO		
Matulic-Adamic; Jasenka	Boulder	CO		
Sweedler; David	Louisville	CO		
Zinnen; Shawn	Denver	CO		

US-CL-CURRENT: 536/25.1; 536/23.1, 536/24.31

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 4. Document ID: US 6471968 B1

L11: Entry 4 of 13

File: USPT

Oct 29, 2002

US-PAT-NO: 6471968

DOCUMENT-IDENTIFIER: US 6471968 B1

TITLE: Multifunctional nanodevice platform

DATE-ISSUED: October 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baker, Jr.; James R.	Ann Arbor	MI		
Tomalia; Donald A.	Ann Arbor	MI		

US-CL-CURRENT: 424/280.1; 424/1.11, 424/130.1, 424/277.1, 424/94.1, 514/44, 536/23.1, 536/24.1, 536/24.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 5. Document ID: US 6447767 B1

L11: Entry 5 of 13

File: USPT

Sep 10, 2002

US-PAT-NO: 6447767

DOCUMENT-IDENTIFIER: US 6447767 B1

TITLE: Non-myeloablative tolerogenic treatment

DATE-ISSUED: September 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Slavin; Shimon	Jerusalem			IL
Prigozhina; Tatyana	Rehovot			IL

US-CL-CURRENT: 424/93.1; 424/93.21, 435/325, 514/2, 514/44

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

☐ 6. Document ID: US 6403630 B1

L11: Entry 6 of 13

File: USPT

Jun 11, 2002

US-PAT-NO: 6403630

DOCUMENT-IDENTIFIER: US 6403630 B1

TITLE: Treating cancers associated with overexpression of HER-2/neu

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dannenberg; Andrew J.	New York	NY		
Subbaramaiah; Kotha	Flushing	NY		

US-CL-CURRENT: 514/406; 424/138.1, 424/155.1, 424/174.1, 514/210.01, 514/247,
514/255.05, 514/341, 514/365, 514/372, 514/374, 514/378, 514/399, 514/400, 514/403,
514/407, 514/602, 514/603, 514/604, 514/605, 514/709

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

☐ 7. Document ID: US 6399063 B1

L11: Entry 7 of 13

File: USPT

Jun 4, 2002

US-PAT-NO: 6399063

DOCUMENT-IDENTIFIER: US 6399063 B1

TITLE: Monoclonal antibodies directed to the HER2 receptor

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hudziak; Robert M.	Corvallis	OR		
Shepard; H. Michael	Rancho Santa Fe	CA		
Ullrich; Axel	Portola Valley	CA		
Fendly; Brian M.	Half Moon Bay	CA		

US-CL-CURRENT: 424/138.1; 424/130.1, 424/133.1, 424/134.1, 424/141.1, 424/142.1,
424/143.1, 424/155.1, 424/156.1, 424/174.1, 424/277.1, 424/85.1, 530/387.3,
530/387.7, 530/388.22, 530/388.8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 8. Document ID: US 6387371 B1

L11: Entry 8 of 13

File: USPT

May 14, 2002

US-PAT-NO: 6387371

DOCUMENT-IDENTIFIER: US 6387371 B1

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies directed to the HER2 receptor

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hudziak; Robert M.	Corvallis	OR		
Shepard; H. Michael	Rancho Santa Fe	CA		
Ullrich; Axel	Portola Valley	CA		
Fendly; Brian M.	Half Moon Bay	CA		

US-CL-CURRENT: 424/138.1; 424/130.1, 424/133.1, 424/143.1, 424/156.1, 424/178.1,
424/198.1, 424/277.1, 424/85.1, 530/387.7, 530/388.85, 530/391.3, 530/391.7, 530/395

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 9. Document ID: US 6333348 B1

L11: Entry 9 of 13

File: USPT

Dec 25, 2001

US-PAT-NO: 6333348

DOCUMENT-IDENTIFIER: US 6333348 B1

TITLE: Use of docetaxel for treating cancers

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vogel; Charles L.	Davie	FL		
Bellet; Robert E.	Elkins Park	PA		

US-CL-CURRENT: 514/449; 424/142.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMNC
Draw Desc	Image									

☐ 10. Document ID: US 6316462 B1

L11: Entry 10 of 13

File: USPT

Nov 13, 2001

US-PAT-NO: 6316462

DOCUMENT-IDENTIFIER: US 6316462 B1

TITLE: Methods of inducing cancer cell death and tumor regression

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bishop; Walter R.	Pompton Plains	NJ		
Brassard; Diana L.	Union	NJ		
Nagabhushan; Tattanahalli L.	Parsippany	NJ		

US-CL-CURRENT: 514/290; 546/80, 549/425

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 11. Document ID: US 6165464 A

L11: Entry 11 of 13

File: USPT

Dec 26, 2000

US-PAT-NO: 6165464

DOCUMENT-IDENTIFIER: US 6165464 A

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies directed to the HER2 receptor

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hudziak; Robert M.	Corvallis	OR		
Shepard; H. Michael	Rancho Santa Fe	CA		
Ullrich; Axel	Portola Valley	CA		
Fendly; Brian M.	Half Moon Bay	CA		

US-CL-CURRENT: 424/142.1; 424/130.1, 424/131.1, 424/143.1, 424/152.1, 424/155.1,
424/156.1, 424/181.1, 424/183.1, 435/330, 435/334, 530/388.15, 530/388.2, 530/388.22,
530/388.8, 530/388.85, 530/389.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 12. Document ID: WO 200241914 A1 AU 200232413 A

L11: Entry 12 of 13

File: DWPI

May 30, 2002

DERWENT-ACC-NO: 2002-599356

DERWENT-WEEK: 200264

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Inhibiting the growth of neoplastic lesions in a patient, comprises administering an antibody against human epidermal growth factor receptor 2 protein and a cGMP-specific phosphodiesterase inhibitor to the patient

INVENTOR: LIU, L; LOBACKI, J M ; PALLANSCH, P J ; THOMPSON, W J

PRIORITY-DATA: 2000US-0716989 (November 21, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200241914 A1	May 30, 2002	E	088	A61K039/395
AU 200232413 A	June 3, 2002		000	A61K039/395

INT-CL (IPC): A01 N 61/00; A61 K 31/00; A61 K 39/395

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

☐ 13. Document ID: WO 200187336 A1 US 20020031515 A1 AU 200161569 A

L11: Entry 13 of 13

File: DWPI

Nov 22, 2001

DERWENT-ACC-NO: 2002-089833

DERWENT-WEEK: 200222

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Treating cancer, in particular breast cancer in a subject, characterized by overexpression of HER2 receptor protein by administering a combination of interleukin-2 and anti-HER2 antibody

INVENTOR: CALIGIURI, M A; MEROPOL, N J ; SCHILSKY, R L

PRIORITY-DATA: 2001US-0855342 (May 14, 2001), 2000US-204284P (May 15, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200187336 A1	November 22, 2001	E	047	A61K039/395
US 20020031515 A1	March 14, 2002		000	A01N037/18
AU 200161569 A	November 26, 2001		000	A61K039/395

INT-CL (IPC): A01 N 37/18; A61 K 38/00; A61 K 38/20; A61 K 39/395; A61 K 45/00; A61 P 35/00; C07 K 1/00; C07 K 14/00; C07 K 16/00; C07 K 17/00; C12 P 21/08; A61 K 39/395; A61 K 38:20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMIC
Draw Desc	Image									

Generate Collection

Print

Terms	Documents
L10 and herceptin	13

Display Format:

[Previous Page](#)

[Next Page](#)

WEST☐ **Generate Collection** **Print**

L17: Entry 3 of 25

File: USPT

Mar 25, 2003

US-PAT-NO: 6537988

DOCUMENT-IDENTIFIER: US 6537988 B2

TITLE: Synergistic methods and compositions for treating cancer

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Francis Y.	Yardley	PA		

US-CL-CURRENT: 514/221; 514/2, 514/449, 514/8, 514/922

CLAIMS:

What is claimed is:

1. A method for the treatment of cancer which comprises administering to a mammalian specie in need thereof a synergistically, therapeutically effective amount of (1) at least one agent selected from the group consisting of anti-proliferative cytotoxic agents and cytostatic agents and (2) a compound of formula I ##STR15##

or a pharmaceutically acceptable salt thereof wherein R.sub.1 is Cl, Br, CN, optionally substituted phenyl, or optionally substituted 2-,3- or 4-pyridyl; R.sub.2 is optionally substituted lower alkyl, or optionally substituted aralkyl; R.sub.3 and R.sub.5 are each independently optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted heterocyclo; R.sub.4 is hydrogen or lower alkyl; Z.sub.1 is CO, SO.sub.2, CO.sub.2 or SO.sub.2 N(R.sub.5)--; and n is 1 or 2;

provided that the cytotoxic agent and/or cytostatic agent is administered simultaneously with or prior to the formula I compound.

2. The method according to claim 1 wherein the cytotoxic agent is administered prior to the formula I compound.

3. The method according to claim 1 wherein the cytotoxic agent comprises radiation therapy.

4. The method according to claim 1, wherein the cytostatic agent is administered prior to the formula I compound.

5. The method according to claim 1 for the synergistic treatment of cancerous solid tumors.

6. The method according to claim 1 wherein the cytotoxic agent is selected from the group consisting of a microtubule-stabilizing agent, a microtubule-disruptor agent, an alkylating agent, an anti-metabolite, epidophyllotoxin, an antineoplastic enzyme, a topoisomerase inhibitor, procarbazine, mitoxantrone, and a platinum coordination complex.

7. The method according to claim 1 wherein the cytotoxic agent is selected from

the group consisting of an anthracycline drug, a vinca drug, a mitomycin, a bleomycin, a cytotoxic nucleoside, a taxane, an epothilone, discodermolide, a pteridine drug, a diynene, an aromatase inhibitor and a podophyllotoxin.

8. The method according to claim 1 wherein the cytotoxic agent is selected from the group consisting of paclitaxel, docetaxel, 7-O-methylthiomethyl-paclitaxel, 4-desacetyl-4-methylcarbonatepaclitaxel, 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel, C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, gemcitabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabine, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, a pyridobenzoindole, an interferon and an interleukin.

9. The method according to claim 1 wherein the cytotoxic agent is selected from the group consisting of a taxane and an epothilone.

10. The method according to claim 1 wherein the cytotoxic agent is selected from the group consisting of paclitaxel, docetaxel, 7-O-methylthiomethyl-paclitaxel, 4-desacetyl-4-methylcarbonatepaclitaxel, 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel, C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione and [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione.

11. The method according to claim 1 wherein R.sub.1 is Br, or CN; R.sub.2 is optionally substituted benzyl; R.sub.3 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl; R.sub.4 is hydrogen, or methyl; Z.sub.1 is CO, SO.sub.2, or SO.sub.2 N(R.sub.5)--; R.sub.5 is optionally substituted lower alkyl or optionally substituted phenyl; and n is 1.

12. The method according to claim 1 wherein R.sub.1 is CN; R.sub.2 is optionally substituted benzyl; R.sub.3 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl; R.sub.4 is hydrogen, or methyl; Z is CO, or SO.sub.2; and n is 1.

13. The method according to claim 1 wherein R.sub.1 is CN; R.sub.2 is benzyl; R.sub.3 is n-propyl, n-butyl, 3-methoxypropyl, 2-thienyl, 5-bromo-2-thienyl, phenyl, 4-methoxyphenyl, or 1-piperidinyl; R.sub.4 is hydrogen; Z is SO.sub.2; and n is 1.

14. The method according to claim 1 wherein the formula I compound is selected from the group consisting of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thi

enylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile;
 (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-4-(1-oxobutyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
 (R)-4-[(5-bromo-2-thienyl)sulfonyl]-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
 (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-4-[(4-methoxyphenyl)sulfonyl]-3-(phenylmethyl)-1H-1,4-benzodiazepine;
 (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(phenylsulfonyl)-1H-1,4-benzodiazepine;
 (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(propylsulfonyl)-1H-1,4-benzodiazepine;
 (R)-4-(butylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
 (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(1-piperidinylsulfonyl)-1H-1,4-benzodiazepine;
 (R)-4-(3-methoxypropylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine; and

pharmaceutically acceptable salts thereof.

15. The method according to claim 14 wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride salt, the methanesulfonic acid salt and the trifluoroacetic acid salt.

16. The method according to claim 10 wherein the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

17. The method according to claim 1 wherein the cytotoxic agent is paclitaxel and the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

18. The method according to claim 1 wherein the cytotoxic agent is [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione and the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

19. The method according to claim 1 wherein the mammalian specie is a human.

20. The method according to claim 1 wherein the cytostatic agent is selected from the group consisting of surgical castration, chemical castration, tamoxifen, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline, 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline, hormone, steroids, steroid synthetic analogs, 17a-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Zoladex, antiangiogenics, matrix metalloproteinase inhibitors, VEGF inhibitors, ZD6474, SU6668, anti-Her2 antibodies, EGFR inhibitors, EKB-569, Imclone antibody C225, src inhibitors, bicalutamide, epidermal growth factor inhibitors, Her-2 inhibitors, MEK-1 kinase inhibitors, MAPK kinase inhibitors, P13 inhibitors, PDGF inhibitors, combretastatins, MET kinase inhibitors, MAP kinase inhibitors, inhibitors of non-receptor and receptor tyrosine kinases, inhibitors of integrin signaling, and inhibitors of insulin-like growth factor receptors.

21. The method according to claim 1, wherein the cytostatic agent is selected from the group consisting of bicalutamide, tamoxifen, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline, Her-1 inhibitors, and trastuzumab.

22. A pharmaceutical composition for the synergistic treatment of cancer which comprises one or both of a cytostatic agent and a cytotoxic agent, and also comprises a compound of formula I as described in claim 1, and a pharmaceutically acceptable carrier.

23. The composition according to claim 22 for the synergistic treatment of cancerous solid tumors.

24. The composition according to claim 22 wherein the cytotoxic agent is one or more antineoplastic agents selected from the group consisting of a microtubule-stabilizing agent, a microtubule-disruptor agent, an alkylating agent, an anti-metabolite, epidophyllotoxin, an antineoplastic enzyme, a topoisomerase inhibitor, procarbazine, mitoxantrone, and a platinum coordination complex.

25. The composition according to claim 22 wherein the cytotoxic agent is one or more antineoplastic agents selected from the group consisting of an anthracycline drug, a vinca drug, a mitomycin, a bleomycin, a cytotoxic nucleoside, a taxane, an epothilone, discodermolide, a pteridine drug, a diynene, an aromatase inhibitor and a podophyllotoxin.

26. The composition according to claim 22 wherein the cytotoxic agent is one or more antineoplastic agents selected from the group consisting of paclitaxel, docetaxel, 7-O-methylthiomethylpaclitaxel, 4-desacetyl-4-methylcarbonatepaclitaxel, 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel, C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo-[14.1.0]heptadecane-5,9-dione, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloro-methotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptapurine, gemcitabine, cytosine arabinoside, podophyllotoxin, etoposide, etoposide phosphate, teniposide, melphalan, vinblastine, vincristine, leurosine, vindesine, leurosine, estramustine, cisplatin, carboplatin, cyclophosphamide, bleomycin, ifosamide, melphalan, hexamethyl melamine, thiotepa, cytarabin, idatrexate, trimetrexate, dacarbazine, L-asparaginase, camptothecin, CPT-11, topotecan, ara-C, bicalutamide, flutamide, leuprolide, a pyridobenzoindole, an interferon and an interleukin.

27. The composition according to claim 22 wherein the cytotoxic agent is one or more cytotoxic agents selected from the group consisting of a taxane and an epothilone.

28. The composition according to claim 22 wherein the cytotoxic agent is one or more antineoplastic agents selected from the group consisting of paclitaxel, docetaxel, 7-O-methylthiomethylpaclitaxel, 4-desacetyl-4-methylcarbonatepaclitaxel, 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel, C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, desoxyepothilone A, desoxyepothilone B, [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione and

[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-3-[2-[2-(aminomethyl)-4-thiazolyl]-1-methylethenyl]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione.

29. The composition according to claim 22, wherein the cytostatic agent is selected from the group consisting of surgical castration, chemical castration, tamoxifen, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline, 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline, hormones, steroids, steroid synthetic analogs, 17 α -Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Zoladex, antiangiogenics, matrix metalloproteinase inhibitors, VEGF inhibitors, ZD6474, SU6668, anti-Her2 antibodies, EGFR inhibitors, EKB-569, Imclone antibody C225, src inhibitors, bicalutamide, epidermal growth factor inhibitors, Her-2 inhibitors, MEK-1 kinase inhibitors, MAPK kinase inhibitors, P13 inhibitors, PDGF inhibitors, combretastatins, MET kinase inhibitors, MAP kinase inhibitors, inhibitors of non-receptor and receptor tyrosine kinases, inhibitors of integrin signaling, and inhibitors of insulin-like growth factor receptors.
30. The composition according to claim 22, wherein the cytostatic agent is selected from the group consisting of bicalutamide, tamoxifen, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline, Her-1 inhibitors, and trastuzumab.
31. The composition according to claim 22 wherein R.sub.1 is Br, or CN; R.sub.2 is optionally substituted benzyl; R.sub.3 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl; R.sub.4 is hydrogen, or methyl; Z.sub.1 is CO, SO.sub.2, or SO.sub.2 N(R.sub.5)--; R.sub.5 is optionally substituted lower alkyl, or optionally substituted phenyl; and n is 1.
32. The composition according to claim 22 wherein R.sub.1 is CN; R.sub.2 is optionally substituted benzyl; R.sub.3 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted 2-thienyl, or optionally substituted 1-piperidinyl; R.sub.4 is hydrogen, or methyl; Z is CO, or SO.sub.2; and n is 1.
33. The composition according to claim 22 wherein R.sub.1 is CN; R.sub.2 is benzyl; R.sub.3 is n-propyl, n-butyl, 3-methoxypropyl, 2-thienyl, 5-bromo-2-thienyl, phenyl, 4-methoxyphenyl, or 1-piperidinyl; R.sub.4 is hydrogen; Z is SO.sub.2; and n is 1.
34. The composition according to claim 22 wherein the formula I compound is selected from the group consisting of
(R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile;
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-4-(1-oxobutyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
(R)-4-[(5-bromo-2-thienyl)sulfonyl]-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-4-[(4-methoxyphenyl)sulfonyl]-3-(phenylmethyl)-1H-1,4-benzodiazepine;
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(phenylsulfonyl)-1H-1,4-benzodiazepine;
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(propylsulfonyl)-1H-1,4-benzodiazepine;
(R)-4-(butylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine;
(R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(1-piperidinylsulfonyl)-1H-1,4-benzodiazepine;
(R)-4-(3-methoxypropylsulfonyl)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-yl

methyl)-3-(phenyl methyl)-1H-1,4-benzodiazepine; and

pharmaceutically acceptable salts thereof.

35. The composition according to claim 34 wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride salt, the methanesulfonic acid salt and the trifluoroacetic acid salt.

36. The composition according to claim 34 wherein the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

37. The composition according to claim 22 wherein the cytotoxic agent is paclitaxel and the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

38. The composition according to claim 22 wherein the cytotoxic agent is [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione and the formula I compound is (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

39. The method according to claim 1 wherein the cancer is a cancer of the prostate, the breast, a non-small cell lung cancer, a metastatic bladder cancer, a colorectal cancer, or a pancreatic cancer.

40. The composition according to claim 22 wherein the cytotoxic agent is one or more cytotoxic agents chosen from the group consisting of paclitaxel, cis-platin, carboplatin, gemcytabine, CPT-11, leucovorin, tegafur, uracil, 5-fluorouracil, 4-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)quinazoline, and 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline).

41. The method according to claim 1 wherein said at least one cytotoxic agent is paclitaxel which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

42. The method according to claim 1 wherein said at least one cytotoxic agent is [1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17-oxabicyclo[14.1.0]heptadecane-5,9-dione which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

43. The method according to claim 1 wherein said at least one cytotoxic agent is CPT-11 which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

44. The method according to claim 1 wherein said at least one cytotoxic agent is gemcitabine or a pharmaceutically acceptable salt thereof which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

45. The method according to claim 1 wherein said at least one cytostatic agent is 4-(3-bromophenylamino)-6,7-bis(methoxy)quinazoline which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

46. The method according to claim 1 wherein said at least one cytostatic agent is trastuzumab which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

47. The method according to claim 1 wherein said at least one cytostatic agent is 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholinyl)propoxy)quinazoline which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

48. The method according to claim 1 wherein said at least one cytostatic agent is tamoxifen which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

49. The method according to claim 1 wherein said at least one cytostatic agent is castration which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

50. The method according to claim 1 wherein said at least one cytotoxic agent is N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide or a pharmaceutically acceptable salt thereof which is administered prior to the administration of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof.

51. The method according to claim 1 wherein said at least one cytotoxic agent is paclitaxel and is administered during about a three hour infusion at about 135 mg/m² followed by a one hour infusion of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof at about 50 mg/m², both paclitaxel and (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof being administered at about three week intervals as needed.

52. The method according to claim 1 wherein said at least one cytotoxic agent is paclitaxel and is administered during about a one hour infusion at about 80 mg/m² followed by about a one hour infusion of (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof at about 80 mg/m², both paclitaxel and (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof being administered at about weekly intervals as needed.

53. The method as claimed in claim 1 wherein two cytotoxic agents are administered, said cytotoxic agents being paclitaxel which is infused for about 3 hours at about 135 mg/m² followed by about a twenty minute infusion of carboplatin at AUC equal to about 6, paclitaxel and carboplatin being

administered at about three week intervals, said method further comprising about weekly administration of
(R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile or a pharmaceutically acceptable salt thereof at about 80 mg/m².



☐

L17: Entry 19 of 25

File: USPT

May 2, 2000

DOCUMENT-IDENTIFIER: US 6056973 A

TITLE: Therapeutic liposome composition and method of preparation

Detailed Description Text (94):

To use the library, a targeting conjugate and a therapeutic liposome composition are selected. Selection of the targeting conjugate is based upon the expression of the conjugate's cognate receptor on individual patient's breast cancer cells. For example, it is common to test for the expression of a variety of receptors on cancer cells obtained from patients during biopsy. Clinical reference laboratories routinely screen biopsy specimens for estrogen receptor status and c-erbB-2 expression status is becoming routine with the clinical development of HERCEPTIN an anti-tumor therapeutic antibody product described by Baselga, et al, (J. Clin Oncol., (3):737-44 (1996)). Exemplary methods for determining c-erbB-2 receptor status are given by Sjogren, et al. (J Clin

WEST

Generate Collection

Print

L17: Entry 20 of 25

File: USPT

Apr 25, 2000

DOCUMENT-IDENTIFIER: US 6054297 A

TITLE: Humanized antibodies and methods for making them

Other Reference Publication (13):

Osborne, Randall, "Full Approval of Breast Cancer Drug Expected by Year's End, FDA Panel OKs Genentech's Herceptin" Daily Ink pp. 1-2 (Sep. 4, 1998).

**End of Result Set**☐

L17: Entry 25 of 25

File: DWPI

Aug 3, 2000

DERWENT-ACC-NO: 2000-505876

DERWENT-WEEK: 200244

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Treating metastasized breast cancer associated with overexpression of
HER-2/neu comprising administering cyclooxygenase-2 inhibitor alone or in combination
with Herceptin (RTM)

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 30 of 32 returned.**☐ 1. Document ID: US 6538174 B2

L18: Entry 1 of 32

File: USPT

Mar 25, 2003

US-PAT-NO: 6538174

DOCUMENT-IDENTIFIER: US 6538174 B2

TITLE: Animal model for transplantation

DATE-ISSUED: March 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Turner; John Harvey	Dalkeith			AU

US-CL-CURRENT: 800/9; 424/93.1, 424/93.2, 424/93.7, 800/10, 800/14, 800/15, 800/16, 800/17, 800/8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[RMC](#)☐ 2. Document ID: US 6534479 B1

L18: Entry 2 of 32

File: USPT

Mar 18, 2003

US-PAT-NO: 6534479

DOCUMENT-IDENTIFIER: US 6534479 B1

TITLE: Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murgita; Robert A.	Montreal			CA

US-CL-CURRENT: 514/12; 424/181.1, 424/183.1, 530/402

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

[RMC](#)☐ 3. Document ID: US 6482618 B2

L18: Entry 3 of 32

File: USPT

Nov 19, 2002

US-PAT-NO: 6482618
DOCUMENT-IDENTIFIER: US 6482618 B2

TITLE: Self-enhancing, pharmacologically controllable expression systems

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Rolf	Marburg			DE
Sedlacek; Hans-Harald	Marburg			DE

US-CL-CURRENT: 435/91.41; 435/320.1, 435/325, 536/23.4, 536/24.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 4. Document ID: US 6428985 B1

L18: Entry 4 of 32

File: USPT

Aug 6, 2002

US-PAT-NO: 6428985
DOCUMENT-IDENTIFIER: US 6428985 B1

TITLE: Immunosuppressive structural definition of IL-10

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bromberg; Jonathan S.	New York	NY		
Ding; YaoZhong	Forest Hills	NY		
Qin; LiHui	New York	NY		

US-CL-CURRENT: 435/69.52; 435/440, 435/445, 435/69.1, 435/69.5, 514/12, 514/2, 514/8,
530/351, 530/387.3, 536/23.1, 536/23.5, 536/23.52, 536/23.72

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 5. Document ID: US 6416734 B1

L18: Entry 5 of 32

File: USPT

Jul 9, 2002

US-PAT-NO: 6416734
DOCUMENT-IDENTIFIER: US 6416734 B1

TITLE: Recombinant alpha-fetoprotein for treating and diagnosing cancers

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Murgita; Robert A.	Montreal			CA

US-CL-CURRENT: 424/1.69; 424/1.11, 424/1.65, 424/9.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 6. Document ID: US 6365357 B1

L18: Entry 6 of 32

File: USPT

Apr 2, 2002

US-PAT-NO: 6365357

DOCUMENT-IDENTIFIER: US 6365357 B1

TITLE: Methods and reagents for preparing and using immunological agents specific for P-glycoprotein

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mechetner; Eugene	Irvine	CA		
Fruehauf; John	Tustin	CA		

US-CL-CURRENT: 435/7.1; 435/4, 435/7.2, 435/7.21, 435/7.23, 530/350, 530/387.1, 530/387.7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 7. Document ID: US 6353011 B1

L18: Entry 7 of 32

File: USPT

Mar 5, 2002

US-PAT-NO: 6353011

DOCUMENT-IDENTIFIER: US 6353011 B1

TITLE: 1,2-dithiolane derivatives

DATE-ISSUED: March 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pershad Singh; Harrihar A.	Bakersfield	CA		
Avery; Mitchell A.	Oxford	MS		

US-CL-CURRENT: 514/369; 548/183, 549/39, 560/9, 562/426

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 8. Document ID: US 6326465 B1

L18: Entry 8 of 32

File: USPT

Dec 4, 2001

US-PAT-NO: 6326465

DOCUMENT-IDENTIFIER: US 6326465 B1

**** See image for Certificate of Correction ****

TITLE: Immunomodulatory polypeptides derived from the invariant chain of MHC class II

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hess; Allan D.	Cockeysville	MD		

US-CL-CURRENT: 530/324; 424/185.1, 424/93.2, 424/93.7, 530/325, 530/326, 530/327,
530/328, 530/329, 530/330, 530/331, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 9. Document ID: US 6313277 B1

L18: Entry 9 of 32

File: USPT

Nov 6, 2001

US-PAT-NO: 6313277

DOCUMENT-IDENTIFIER: US 6313277 B1

TITLE: Breast cancer resistance protein (BCRP) and the DNA which encodes it

DATE-ISSUED: November 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas D.	Columbia	MD		
Doyle; L. Austin	Silver Spring	MD		
Abruzzo; Lynne V.	Potomac	MD		

US-CL-CURRENT: 536/23.1; 435/252.3, 435/320.1, 435/69.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 10. Document ID: US 6303312 B1

L18: Entry 10 of 32

File: USPT

Oct 16, 2001

US-PAT-NO: 6303312

DOCUMENT-IDENTIFIER: US 6303312 B1

TITLE: Complex formation between dsDNA and oligomer of cyclic heterocycles

DATE-ISSUED: October 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dervan; Peter B.	San Marino	CA		
Gottesfeld; Joel M.	Del Mar	CA		

US-CL-CURRENT: 435/6; 536/26.6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 11. Document ID: US 6281015 B1

L18: Entry 11 of 32

File: USPT

Aug 28, 2001

US-PAT-NO: 6281015

DOCUMENT-IDENTIFIER: US 6281015 B1

**** See image for Certificate of Correction ****

TITLE: Localized delivery of factors enhancing survival of transplanted cells

DATE-ISSUED: August 28, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mooney; David J.	Ann Arbor	MI		
Langer; Robert S.	Newton	MA		
Vacanti; Joseph P.	Winchester	MA		

US-CL-CURRENT: 435/395; 424/457, 424/462, 424/93.7, 435/325, 435/405, 514/3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 12. Document ID: US 6255452 B1

L18: Entry 12 of 32

File: USPT

Jul 3, 2001

US-PAT-NO: 6255452

DOCUMENT-IDENTIFIER: US 6255452 B1

TITLE: Epidermal growth factor inhibitor

DATE-ISSUED: July 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Strayer; David S.	Newtown Square	PA		

US-CL-CURRENT: 530/324; 530/327

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 13. Document ID: US 6238644 B1

L18: Entry 13 of 32

File: USPT

May 29, 2001

US-PAT-NO: 6238644

DOCUMENT-IDENTIFIER: US 6238644 B1

TITLE: Method for treating and/or imaging breast cancer using radioactive iodide

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rillema; James A.	Bloomfield Hills	MI		

US-CL-CURRENT: 424/1.61; 424/1.65, 424/1.85

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 14. Document ID: US 6225325 B1

L18: Entry 14 of 32

File: USPT

May 1, 2001

US-PAT-NO: 6225325

DOCUMENT-IDENTIFIER: US 6225325 B1

TITLE: Use of alkylated iminosugars to treat multidrug resistance

DATE-ISSUED: May 1, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jacob; Gary S.	Creve Coeur	MI		

US-CL-CURRENT: 514/328

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 15. Document ID: US 5998140 A

L18: Entry 15 of 32

File: USPT

Dec 7, 1999

US-PAT-NO: 5998140

DOCUMENT-IDENTIFIER: US 5998140 A

TITLE: Complex formation between dsDNA and oligomer of cyclic heterocycles

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dervan; Peter B.	San Marino	CA		
Gottesfeld; Joel M.	Del Mar	CA		

US-CL-CURRENT: 435/6; 536/24.3, 536/24.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 16. Document ID: US 5846720 A

L18: Entry 16 of 32

File: USPT

Dec 8, 1998

US-PAT-NO: 5846720

DOCUMENT-IDENTIFIER: US 5846720 A

TITLE: Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Foulkes; J. Gordon	Huntington Station	NY		
Liechtfried; Franz E.	Vienna			AT
Pieler; Christian	Vienna			AT
Stephenson; John R.	Santa Cruz	CA		
Case; Casey C.	Lynbrook	NY		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.8, 435/91.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 17. Document ID: US 5811452 A

L18: Entry 17 of 32

File: USPT

Sep 22, 1998

US-PAT-NO: 5811452

DOCUMENT-IDENTIFIER: US 5811452 A

**** See image for Certificate of Correction ****

TITLE: Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ojima; Iwao	Stony Brook	NY		
Bernacki; Ralph J.	Elma	NY		

US-CL-CURRENT: [514/449](#); [549/510](#), [549/511](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 18. Document ID: US 5674887 A

L18: Entry 18 of 32

File: USPT

Oct 7, 1997

US-PAT-NO: 5674887

DOCUMENT-IDENTIFIER: US 5674887 A

TITLE: Prevention of bone resorption

DATE-ISSUED: October 7, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blake; David R.	Worcs.			GB
Panetta; Jill A.	Zionsville	IN		
Zaidi; Mone	Middlesex			GB

US-CL-CURRENT: [514/407](#); [514/406](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 19. Document ID: US 5656267 A

L18: Entry 19 of 32

File: USPT

Aug 12, 1997

US-PAT-NO: 5656267

DOCUMENT-IDENTIFIER: US 5656267 A

TITLE: Implantable cells that alleviate chronic pain in humans

DATE-ISSUED: August 12, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sagen; Jacqueline	Chicago	IL	60645	
Pappas; George Demetrios	Chicago	IL	60657	

US-CL-CURRENT: [424/93.21](#); [424/520](#), [424/563](#), [424/570](#), [514/44](#), [604/522](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

☐ 20. Document ID: US 5580722 A

L18: Entry 20 of 32

File: USPT

Dec 3, 1996

US-PAT-NO: 5580722
DOCUMENT-IDENTIFIER: US 5580722 A

TITLE: Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Foulkes; J. Gordon	Huntington Station	NY		
Liechtfried; Franz E.	Vienna			AT
Pieler; Christian	Vienna			AT
Stephenson; John R.	Santa Cruz	CA		
Case; Casey C.	Lynbrook	NY		

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 21. Document ID: US 5569463 A

L18: Entry 21 of 32

File: USPT

Oct 29, 1996

US-PAT-NO: 5569463
DOCUMENT-IDENTIFIER: US 5569463 A

TITLE: Medical device polymer

DATE-ISSUED: October 29, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Helmus; Michael N.	Worcester	MA		
Tolkoff; M. Joshua	Brookline	MA		
Raleigh; Carol L.	Weston	MA		

US-CL-CURRENT: 424/426; 424/423, 424/424, 424/425, 424/450, 427/2.12, 514/772.2, 514/822, 523/112, 523/113, 604/266, 604/508

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMOC
Draw Desc	Image									

☐ 22. Document ID: US 5550114 A

L18: Entry 22 of 32

File: USPT

Aug 27, 1996

US-PAT-NO: 5550114
DOCUMENT-IDENTIFIER: US 5550114 A

TITLE: Epidermal growth factor inhibitor

DATE-ISSUED: August 27, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Strayer; David S.	Newton Square	PA		

US-CL-CURRENT: 514/21; 530/350, 530/399, 530/417

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 23. Document ID: US 5447724 A

L18: Entry 23 of 32

File: USPT

Sep 5, 1995

US-PAT-NO: 5447724

DOCUMENT-IDENTIFIER: US 5447724 A

**** See image for Certificate of Correction ****

TITLE: Medical device polymer

DATE-ISSUED: September 5, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Helmus; Michael N.	Worcester	MA		
Tolkoff; M. Joshua	Brookline	MA		
Raleigh; Carol L.	Weston	MA		

US-CL-CURRENT: 424/426; 424/423, 424/424, 424/425, 424/450, 427/2.12, 514/772.2,
514/822, 523/112, 523/113, 604/266, 604/507

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 24. Document ID: US 5436258 A

L18: Entry 24 of 32

File: USPT

Jul 25, 1995

US-PAT-NO: 5436258

DOCUMENT-IDENTIFIER: US 5436258 A

TITLE: Prevention of bone resorption

DATE-ISSUED: July 25, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Blake; David R.	Worcs			GB
Panetta; Jill A.	Zionsville	IN		
Zaidi; Mone	Middlesex			GB

US-CL-CURRENT: 514/372; 514/403, 514/404

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 25. Document ID: US 5422115 A

L18: Entry 25 of 32

File: USPT

Jun 6, 1995

US-PAT-NO: 5422115

DOCUMENT-IDENTIFIER: US 5422115 A

TITLE: Methods of treatment and devices employing lithium salts

DATE-ISSUED: June 6, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Horrobin; David F.	Haslemere			GB

US-CL-CURRENT: 424/422; 424/423, 424/436, 424/474, 424/475, 424/480, 424/482,
514/810, 514/821, 514/824, 514/825, 514/866, 514/885, 514/886, 514/931, 514/934

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 26. Document ID: US 5252333 A

L18: Entry 26 of 32

File: USPT

Oct 12, 1993

US-PAT-NO: 5252333

DOCUMENT-IDENTIFIER: US 5252333 A

TITLE: Lithium salt-containing pharmaceutical compositions

DATE-ISSUED: October 12, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Horrobin; David F.	Haslemere			GB

US-CL-CURRENT: 424/422; 424/445, 424/449, 424/463, 424/474, 424/490, 514/905, 514/943

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 27. Document ID: WO 200253138 A2

L18: Entry 27 of 32

File: DWPI

Jul 11, 2002

DERWENT-ACC-NO: 2002-706847

DERWENT-WEEK: 200276

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Composition useful in the treatment of cancer comprises at least one of incensole or furanogermacrene

INVENTOR: SHANAHAN-PRENDERGAST, E

PRIORITY-DATA: 2001IE-0000002 (January 2, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200253138 A2	July 11, 2002	E	068	A61K031/00

INT-CL (IPC): A61 K 31/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Clip Img	Image								

☐ 28. Document ID: US 20020143062 A1 WO 200232413 A2 AU 200211776 A

L18: Entry 28 of 32

File: DWPI

Oct 3, 2002

DERWENT-ACC-NO: 2002-519137

DERWENT-WEEK: 200267

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Preparation of a retinoid composition, useful for treating cancer, involves mixing at least one retinoid or its derivative with dimyristoyl phosphatidylcholine, soybean oil, tertiarybutyl alcohol and water

INVENTOR: LIM, S; LOPEZ-BERESTEIN, G ; TARI, A M

PRIORITY-DATA: 2000US-241445P (October 17, 2000), 2001US-0982113 (October 17, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020143062 A1	October 3, 2002		000	A61K039/395
WO 200232413 A2	April 25, 2002	E	112	A61K031/00
AU 200211776 A	April 29, 2002		000	A61K031/00

INT-CL (IPC): A61 K 9/127; A61 K 31/00; A61 K 31/16; A61 K 39/395

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 29. Document ID: JP 2002540119 W WO 200056757 A1 AU 200039190 A EP 1163256 A1 NO 200104588 A BR 200009476 A CZ 200103420 A3 KR 2002003217 A CN 1355809 A

L18: Entry 29 of 32

File: DWPI

Nov 26, 2002

DERWENT-ACC-NO: 2000-611626

DERWENT-WEEK: 200307

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Use of new and known androstan-17-one derivatives as immunomodulators to treat, prevent and delay e.g. viral, bacterial, fungal and protozoal infections, cancers, wounds, burns, Crohn's disease, diabetes and autoimmune diseases

INVENTOR: AHLEM, C N; DOS ANJOS DE CARVALHO, L D ; FRINCKE, J M ; HEGGIE, W ;

PRENDERGAST, P T ; READING, C L ; THADIKONDA, K P ; VERNON, R N ; DE CARVALHO, L D D
A ; DE CARVALHO DOS ANJOS, L D ; HEGGIE, W R ; THADIKONDA, P K

PRIORITY-DATA: 1999US-164048P (November 8, 1999), 1999US-126056P (March 23, 1999),
1999US-140028P (June 16, 1999), 1999US-0414905 (October 8, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002540119 W	November 26, 2002		339	C07J001/00
WO 200056757 A1	September 28, 2000	E	244	C07J001/00
AU 200039190 A	October 9, 2000		000	C07J001/00
EP 1163256 A1	December 19, 2001	E	000	C07J001/00
NO 200104588 A	November 21, 2001		000	C07J000/00
BR 200009476 A	February 19, 2002		000	C07J001/00
CZ 200103420 A3	April 17, 2002		000	C07J001/00
KR 2002003217 A	January 10, 2002		000	C07J001/00
CN 1355809 A	June 26, 2002		000	C07J001/00

INT-CL (IPC): A61 K 31/565; A61 K 31/5685; A61 K 31/58; A61 P 31/04; A61 P 31/12; A61
P 31/18; A61 P 31/20; A61 P 33/00; A61 P 35/00; A61 P 37/00; C07 J 0/00; C07 J 1/00;
C07 J 3/00; C07 J 9/00; C07 J 17/00; C07 J 53/00; C07 J 73/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Clip Img	Image								

☐ 30. Document ID: WO 9838320 A1 JP 2001513636 W AU 9863038 A ZA 9801535 A EP
1012305 A1

L18: Entry 30 of 32

File: DWPI

Sep 3, 1998

DERWENT-ACC-NO: 1998-481214

DERWENT-WEEK: 200165

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New isolated bromelain component protein - used for e.g. treating cancers,
immuno: deficiency(s) or diseases which respond to increased nitric oxide production
or as a vaccine adjuvant or antimicrobial agent

INVENTOR: ENGWERDA, C; MYNOTT, T L ; PEEK, K

PRIORITY-DATA: 1997GB-0004252 (February 28, 1997), 1997GB-0003827 (February 25,
1997), 1997GB-0003850 (February 25, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9838320 A1	September 3, 1998	E	061	C12N015/57
JP 2001513636 W	September 4, 2001		127	C12N015/09
AU 9863038 A	September 18, 1998		000	C12N015/57
ZA 9801535 A	November 24, 1999		044	C12N000/00
EP 1012305 A1	June 28, 2000	E	000	C12N015/57

INT-CL (IPC): A61 K 38/46; A61 K 38/48; A61 K 39/39; A61 P 3/10; A61 P 17/02; A61 P
31/04; A61 P 31/18; A61 P 33/06; A61 P 35/00; A61 P 37/04; A61 P 43/00; C07 H 0/00;
C07 K 0/00; C12 N 0/00; C12 N 9/50; C12 N 15/09; C12 N 15/57

WEST Search History

DATE: Thursday, April 10, 2003

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
L18	cyclosporin\$ same breast	32	L18
L17	herceptin same breast	25	L17
L16	herceptin same retino\$	2	L16
L15	herceptin adj10 retino\$	0	L15
L14	L13 and retino\$	16	L14
L13	(combination adj1 \$therapy) same cyclosporin\$	162	L13
L12	L10 and cyclosporin	381	L12
L11	L10 and herceptin	13	L11
L10	combination adj1 \$therapy	4099	L10
L9	l8 and retino\$	18	L9
L8	L7 and ((424/450)!.CCLS.)	46	L8
L7	L5 and target\$	236	L7
L6	L5 and antibod\$	215	L6
L5	L2 and peg	250	L5
L4	L3 and retino\$	24	L4
L3	L2 and (soybean adj1 oil)	35	L3
L2	liposome\$ same dimyristoyl\$	597	L2
L1	liposome\$ same (tertiary adj1 butyl)	22	L1

END OF SEARCH HISTORY

WEST

Generate Collection

Print

Search Results - Record(s) 1 through 30 of 63 returned.☐ 1. Document ID: US 6545170 B2

L3: Entry 1 of 63

File: USPT

Apr 8, 2003

US-PAT-NO: 6545170

DOCUMENT-IDENTIFIER: US 6545170 B2

TITLE: 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pitzele; Barnett S.	Skokie	IL		
Sikorski; James A.	Kirkwood	MO		
Hansen, Jr.; Donald W.	Skokie	IL		
Webber; Ronald Keith	St. Charles	MO		
Toth; Mihaly V.	St. Louis	MO		
Scholten; Jeffrey A.	Chesterfield	MO		
Snyder; Jeffrey S.	Manchester	MO		

US-CL-CURRENT: 554/104; 562/439

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	NOTE
Draw Desc	Image									

☐ 2. Document ID: US 6545097 B2

L3: Entry 2 of 63

File: USPT

Apr 8, 2003

US-PAT-NO: 6545097

DOCUMENT-IDENTIFIER: US 6545097 B2

TITLE: Drug delivery compositions and medical devices containing block copolymer

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pinchuk; Leonard	Miami	FL		
Nott; Sepideh	Weston	MA		
Schwarz; Marlene	Newton	MA		
Kamath; Kalpana	Natick	MA		

US-CL-CURRENT: 525/240; 424/423, 424/501, 525/221, 525/242

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 3. Document ID: US 6545049 B1

L3: Entry 3 of 63

File: USPT

Apr 8, 2003

US-PAT-NO: 6545049

DOCUMENT-IDENTIFIER: US 6545049 B1

TITLE: Dimer-selective RXR modulators and methods for their use

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Canan-Koch; Stacie	San Diego	CA		
Hwang; Chan K.	Boulder	CO		
Boehm; Marcus F.	San Diego	CA		
Badea; Beth Ann	San Diego	CA		
Dardashti; Laura J.	Santa Anna	CA		
Zhang; Lin	San Diego	CA		
Nadzan; Alex M.	San Diego	CA		
Heyman; Richard A.	Encinitas	CA		
Mukherjee; Ranjan	San Diego	CA		
Lala; Deepak S.	San Diego	CA		
Farmer; Luc J.	La Jolla	CA		

US-CL-CURRENT: [514/569](#); [514/725](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 4. Document ID: US 6530951 B1

L3: Entry 4 of 63

File: USPT

Mar 11, 2003

US-PAT-NO: 6530951

DOCUMENT-IDENTIFIER: US 6530951 B1

TITLE: Silver implantable medical device

DATE-ISSUED: March 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bates; Brian L.	Bloomington	IN		
Fearnot; Neal E.	West Lafayette	IN		
Kozma; Thomas G.	West Lafayette	IN		
Osborne; Thomas A.	Bloomington	IN		
Ragheb; Anthony O.	West Lafayette	IN		
Roberts; Joseph W.	St. Paul	MN		
Voorhees, III; William D.	West Lafayette	IN		

US-CL-CURRENT: 623/1.45; 606/192, 606/194, 606/198, 623/1.15, 623/1.44, 623/1.46

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

☐ 5. Document ID: US 6524583 B1

L3: Entry 5 of 63

File: USPT

Feb 25, 2003

US-PAT-NO: 6524583

DOCUMENT-IDENTIFIER: US 6524583 B1

TITLE: Antibody methods for selectively inhibiting VEGF

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Brekken; Rolf A.	Seattle	WA		

US-CL-CURRENT: 424/145.1; 424/133.1, 424/135.1, 424/141.1, 530/387.1, 530/388.1, 530/388.15, 530/388.25, 530/809, 530/864, 530/865, 530/866

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMC
Draw Desc	Image									

☐ 6. Document ID: US 6511800 B1

L3: Entry 6 of 63

File: USPT

Jan 28, 2003

US-PAT-NO: 6511800

DOCUMENT-IDENTIFIER: US 6511800 B1

TITLE: Methods of treating nitric oxide and cytokine mediated disorders

DATE-ISSUED: January 28, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Singh; Inderjit	Mount Pleasant	SC		

US-CL-CURRENT: 435/4; 435/26

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMK
Draw Desc	Image									

☐ 7. Document ID: US 6495604 B1

L3: Entry 7 of 63

File: USPT

Dec 17, 2002

US-PAT-NO: 6495604

DOCUMENT-IDENTIFIER: US 6495604 B1

TITLE: Cycloalkene derivatives, process for producing the same, and use

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ichimori; Yuzo	Sakai			JP
Ii; Masayuki	Minoo			JP
Itoh; Katsumi	Osaka			JP
Kitazaki; Tomoyuki	Kobe			JP
Yamada; Junji	Hikari			JP

US-CL-CURRENT: 514/602; 514/359, 514/373, 514/383, 514/520, 514/521, 514/522,
514/529, 514/530, 514/538, 514/562, 514/601, 514/603, 514/604, 548/166, 548/250,
548/252, 548/253, 548/255, 548/269.4, 558/418, 560/12, 560/13, 562/430, 564/91,
564/92

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMK
Draw Desc	Image									

☐ 8. Document ID: US 6495544 B2

L3: Entry 8 of 63

File: USPT

Dec 17, 2002

US-PAT-NO: 6495544

DOCUMENT-IDENTIFIER: US 6495544 B2

TITLE: Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hansen, Jr.; Donald W.	Skokie	IL		
Snyder; Jeffrey S.	Manchester	MO		
Moormann; Alan E.	Weldon Springs	MO		
Awasthi; Alok K.	Skokie	IL		
Webber; Ronald Keith	St. Charles	MO		
Franczyk; Thaddeus S.	Chesterfield	MO		
Trivedi; Mahima	Skokie	IL		

US-CL-CURRENT: 514/217.11; 540/531, 540/552, 540/604, 540/605

Full	Title	Station	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 9. Document ID: US 6482861 B2

L3: Entry 9 of 63

File: USPT

Nov 19, 2002

US-PAT-NO: 6482861

DOCUMENT-IDENTIFIER: US 6482861 B2

TITLE: Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Duane D.	Germantown	TN		
Kirkovsky; Leonid I.	Memphis	TN		
Dalton; James T.	Memphis	TN		
Mukherjee; Arnab	Memphis	TN		

US-CL-CURRENT: 514/617; 514/150, 514/508, 514/519, 514/522, 514/618, 514/619, 514/620

Full	Title	Station	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 10. Document ID: US 6465686 B2

L3: Entry 10 of 63

File: USPT

Oct 15, 2002

US-PAT-NO: 6465686

DOCUMENT-IDENTIFIER: US 6465686 B2

TITLE: Halogenated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Grapperhaus; Margaret L.	Troy	IL		
Sikorski; James A.	St. Louis	MO		
Awasthi; Alok K.	Skokie	IL		
Wang; Lijuan J.	Wildwood	MO		
Pitzele; Barnett S.	Skokie	IL		
Hansen, Jr.; Donald W.	Skokie	IL		
Manning; Pamela T.	Labadie	MO		

US-CL-CURRENT: 562/439; 560/125, 560/155, 560/168, 560/172, 560/34, 562/507, 562/512, 562/540, 562/560, 562/561, 562/602, 564/193, 564/230

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 11. Document ID: US 6465518 B2

L3: Entry 11 of 63

File: USPT

Oct 15, 2002

US-PAT-NO: 6465518

DOCUMENT-IDENTIFIER: US 6465518 B2

TITLE: Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hansen, Jr.; Donald W.	Skokie	IL		
Webber; Ronald Keith	St. Charles	MO		
Awasthi; Alok K.	Skokie	IL		
Manning; Pamela T.	Labadie	MO		

US-CL-CURRENT: 514/565; 562/560

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 12. Document ID: US 6462075 B1

L3: Entry 12 of 63

File: USPT

Oct 8, 2002

US-PAT-NO: 6462075

DOCUMENT-IDENTIFIER: US 6462075 B1

TITLE: Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bowen; J. Phillip	Hull	GA		
Robinson; Thomas Phillip	Durham	NC		
Ehlers; Tedman	Athens	GA		
Goldsmith; David	Atlanta	GA		
Arbiser; Jack	Atlanta	GA		

US-CL-CURRENT: 514/460; 514/685, 514/729, 549/401, 568/326, 568/334

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 13. Document ID: US 6441027 B1

L3: Entry 13 of 63

File: USPT

Aug 27, 2002

US-PAT-NO: 6441027

DOCUMENT-IDENTIFIER: US 6441027 B1

TITLE: Method of regulating the female reproductive system through angiogenesis inhibitors

DATE-ISSUED: August 27, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
D'Amato; Robert J.	Lexington	MA		
Demore; Nancy Klauber	Durham	NC		

US-CL-CURRENT: 514/450

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 14. Document ID: US 6432947 B1

L3: Entry 14 of 63

File: USPT

Aug 13, 2002

US-PAT-NO: 6432947

DOCUMENT-IDENTIFIER: US 6432947 B1

TITLE: N-heterocyclic derivatives as NOS inhibitors

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Arnaiz; Damian O.	Hercules	CA		
Baldwin; John J.	Gwynedd Valley	PA		
Davey; David D.	El Sobrante	CA		
Devlin; James J.	Lafayette	CA		
Dolle, III; Roland Ellwood	King of Prussia	PA		
Erickson; Shawn David	New York	NY		
McMillan; Kirk	Trenton	NJ		
Morrissey; Michael M.	Danville	CA		
Ohlmeyer; Michael H. J.	Plainsboro	NJ		
Pan; Gonghua	Groton	CT		
Paradkar; Vidyadhar Madhav	Somerville	NJ		
Parkinson; John	Martinez	CA		
Phillips; Gary B.	Pleasant Hill	CA		
Ye; Bin	Richmond	CA		
Zhao; Zuchun	El Sobrante	CA		

US-CL-CURRENT: 514/227.8; 514/235.8, 514/252.19, 514/273, 514/275, 544/122, 544/295,
544/298, 544/320, 544/324, 544/331, 544/58.6, 544/60

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 15. Document ID: US 6403830 B2

L3: Entry 15 of 63

File: USPT

Jun 11, 2002

US-PAT-NO: 6403830

DOCUMENT-IDENTIFIER: US 6403830 B2

TITLE: Amidino compound and salts thereof useful as nitric oxide synthase inhibitors

DATE-ISSUED: June 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Webber; Ronald Keith	St. Charles	MO		
Durley; Richard C.	Chesterfield	MO		
Awasthi; Alok K.	Skokie	IL		
Bergmanis; Arija A.	Des Plaines	IL		
Ganser; Scott S.	Chicago	IL		
Hagen; Timothy J.	Gurne	IL		
Hallinan; E. Ann	Evanston	IL		
Hansen, Jr.; Donald W.	Skokie	IL		
Hickory; Brian S.	Wildwood	MO		
Moormann; Alan E.	Weldon Springs	MO		
Pitzele; Barnett S.	Skokie	IL		
Promo; Michelle A.	Chesterfield	MO		
Schartman; Richard R.	Evanston	IL		
Snyder; Jeffrey S.	Manchester	MO		
Trivedi; Mahima	Glenview	IL		
Tsymbalov; Sofya	Skokie	IL		

US-CL-CURRENT: 562/557; 544/158, 548/534, 548/535

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 16. Document ID: US 6335170 B1

L3: Entry 16 of 63

File: USPT

Jan 1, 2002

US-PAT-NO: 6335170

DOCUMENT-IDENTIFIER: US 6335170 B1

TITLE: Gene expression in bladder tumors

DATE-ISSUED: January 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Orntoft; Torben F.	DK 8230 Aabyhoj			DK

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/24.3, 536/24.31, 536/24.33

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 17. Document ID: US 6326507 B1

L3: Entry 17 of 63

File: USPT

Dec 4, 2001

US-PAT-NO: 6326507

DOCUMENT-IDENTIFIER: US 6326507 B1

**** See image for Certificate of Correction ****

TITLE: Therapeutic compounds and methods of use

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gribble; Gordon W.	Norwich	VT		
Honda; Tadashi	Hanover	NH		
Sporn; Michael B.	Tunbridge	VT		
Suh; Nanjoo	Hanover	NH		

US-CL-CURRENT: 558/415; 558/423

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMC
Draw Desc	Image									

☐ 18. Document ID: US 6316502 B1

L3: Entry 18 of 63

File: USPT

Nov 13, 2001

US-PAT-NO: 6316502

DOCUMENT-IDENTIFIER: US 6316502 B1

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		
Vassilev; Vassil	San Diego	CA		

US-CL-CURRENT: 514/599; 514/707, 514/825, 514/838, 514/851, 514/861, 514/866,
514/885, 514/903, 514/912, 514/925

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 19. Document ID: US 6299604 B1

L3: Entry 19 of 63

File: USPT

Oct 9, 2001

US-PAT-NO: 6299604

DOCUMENT-IDENTIFIER: US 6299604 B1

TITLE: Coated implantable medical device

DATE-ISSUED: October 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ragheb; Anthony O.	West Lafayette	IN		
Bates; Brian L.	Bloomington	IN		
Fearnott; Neal E.	West Lafayette	IN		
Kozma; Thomas G.	Lafayette	IN		
Voorhees, III; William D.	West Lafayette	IN		

US-CL-CURRENT: 604/265; 623/1.15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 20. Document ID: US 6231894 B1

L3: Entry 20 of 63

File: USPT

May 15, 2001

US-PAT-NO: 6231894

DOCUMENT-IDENTIFIER: US 6231894 B1

**** See image for Certificate of Correction ****

TITLE: Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase

DATE-ISSUED: May 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stamler; Jonathan S.	Chapel Hill	NC		
Day; Brian J.	Englewood	CO		
Gross; Steven S.	New York	NY		
Griffith; Owen W.	Milwaukee	WI		

US-CL-CURRENT: 424/718; 514/340, 514/610

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 21. Document ID: US 6228983 B1

L3: Entry 21 of 63

File: USPT

May 8, 2001

US-PAT-NO: 6228983

DOCUMENT-IDENTIFIER: US 6228983 B1

**** See image for Certificate of Correction ****

TITLE: Human respiratory syncytial virus peptides with antifusogenic and antiviral activities

DATE-ISSUED: May 8, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn O'Lin	Cary	NC		
Lambert; Dennis Michael	Cary	NC		
Petteway; Stephen Robert	Cary	NC		

US-CL-CURRENT: 530/300; 424/186.1, 424/211.1, 530/324, 530/325, 530/326

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 22. Document ID: US 6228845 B1

L3: Entry 22 of 63

File: USPT

May 8, 2001

US-PAT-NO: 6228845

DOCUMENT-IDENTIFIER: US 6228845 B1

TITLE: Therapeutic intraluminal stents

DATE-ISSUED: May 8, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Donovan; Maura G.	St. Paul	MN		
Stein; Paul M.	Maple Grove	MN		

US-CL-CURRENT: 514/44; 264/279, 264/314, 264/485, 424/93.21, 604/1, 604/265, 604/523

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KVMC
Draw Desc	Image									

☐ 23. Document ID: US 6210923 B1

L3: Entry 23 of 63

File: USPT

Apr 3, 2001

US-PAT-NO: 6210923

DOCUMENT-IDENTIFIER: US 6210923 B1

TITLE: Mammalian circadian regulator M-RIGUI2 (MPER2)

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Cheng-Chi	Houston	TX		
Albrecht; Urs	Houston	TX		
Eichele; Gregor	Houston	TX		
Sun; Zhong-Sheng	Houston	TX		

US-CL-CURRENT: 435/69.1; 435/252.3, 435/320.1, 435/325, 435/348, 435/6, 530/350,
536/23.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 24. Document ID: US 6180355 B1

L3: Entry 24 of 63

File: USPT

Jan 30, 2001

US-PAT-NO: 6180355

DOCUMENT-IDENTIFIER: US 6180355 B1

**** See image for Certificate of Correction ****

TITLE: Method for diagnosing and treating chronic pelvic pain syndrome

DATE-ISSUED: January 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alexander; Richard B.	Ellicott City	MD		
Ponniah; Sathibalan	Ellicott City	MD		

US-CL-CURRENT: 435/7.1; 435/7.8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	None
Draw Desc	Image									

☐ 25. Document ID: US 6177272 B1

L3: Entry 25 of 63

File: USPT

Jan 23, 2001

US-PAT-NO: 6177272

DOCUMENT-IDENTIFIER: US 6177272 B1

TITLE: Method for treating vascular proliferative diseases with p27 and fusions thereof

DATE-ISSUED: January 23, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nabel; Gary J.	Ann Arbor	MI		
Nabel; Elizabeth G.	Ann Arbor	MI		

US-CL-CURRENT: [435/320.1](#); [435/455](#), [530/350](#), [536/23.1](#), [536/23.4](#), [536/23.5](#), [536/24.1](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KM/C
Draw Desc	Image									

☐ 26. Document ID: US 6160011 A

L3: Entry 26 of 63

File: USPT

Dec 12, 2000

US-PAT-NO: 6160011

DOCUMENT-IDENTIFIER: US 6160011 A

TITLE: Non-steroidal agonist compounds and their use in male hormone therapy

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Duane D.	Germantown	TN		
Kirkovsky; Leonid I.	Memphis	TN		
Dalton; James T.	Memphis	TN		
Mukherjee; Arnab	Memphis	TN		

US-CL-CURRENT: [514/522](#); [514/524](#), [514/616](#), [514/628](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KM/C
Draw Desc	Image									

☐ 27. Document ID: US 6096070 A

L3: Entry 27 of 63

File: USPT

Aug 1, 2000

US-PAT-NO: 6096070

DOCUMENT-IDENTIFIER: US 6096070 A

TITLE: Coated implantable medical device

DATE-ISSUED: August 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ragheb; Anthony O.	West Lafayette	IN		
Bates; Brian L.	Bloomington	IN		
Fearnot; Neal E.	West Lafayette	IN		
Kozma; Thomas G.	West Lafayette	IN		
Voorhees, III; William D.	West Lafayette	IN		

US-CL-CURRENT: [623/1.39](#); [604/265](#), [604/508](#), [623/1.44](#), [623/1.49](#), [623/23.71](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KM/C
Draw Desc	Image									

☐ 28. Document ID: US 6093794 A

L3: Entry 28 of 63

File: USPT

Jul 25, 2000

US-PAT-NO: 6093794

DOCUMENT-IDENTIFIER: US 6093794 A

TITLE: Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barney; Shawn O'Lin	Cary	NC		
Lambert; Dennis Michael	Cary	NC		
Petteway; Stephen Robert	Cary	NC		

US-CL-CURRENT: 530/300; 424/186.1, 424/230.1, 530/324, 530/325, 530/326, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMG
Draw Desc	Image									

☐ 29. Document ID: US 6093743 A

L3: Entry 29 of 63

File: USPT

Jul 25, 2000

US-PAT-NO: 6093743

DOCUMENT-IDENTIFIER: US 6093743 A

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lai; Ching-San	Encinitas	CA		
Vassilev; Vassil	San Diego	CA		

US-CL-CURRENT: 514/599; 514/706, 514/707, 514/851, 514/861, 514/863, 514/866, 514/909, 514/912

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RMG
Draw Desc	Image									

☐ 30. Document ID: US 6077673 A

L3: Entry 30 of 63

File: USPT

Jun 20, 2000

US-PAT-NO: 6077673

DOCUMENT-IDENTIFIER: US 6077673 A

TITLE: Mouse arrays and kits comprising the same

DATE-ISSUED: June 20, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chenchik; Alex	Palo Alto	CA		
Lukashev; Matvey	Newton	MA		

US-CL-CURRENT: 435/6; 422/68.1, 435/283.1, 435/285.1, 435/286.1, 435/286.2,
435/287.1, 435/287.2, 435/287.7, 435/287.9, 435/289.1, 435/299.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

Generate Collection

Print

Terms	Documents
L2 and (cancer\$ or neoplas\$)	63

Display Format:

-

Change Format

[Previous Page](#)

[Next Page](#)